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Abstract 
In the first part of the project, two highly functionalized terminal alkynes, 3,3,4,4-
tetraethoxybut-1-yne (TEB) and 1,1-diethoxy-but-3-yn-2-one (keto-TEB) have been 
used for the synthesis of 1,4-disubstituted 1,2,3-triazoles. These 1,4-disubstituted 
1,2,3-triazoles have also been converted into their corresponding N-unsubstituted 
1,2,3-triazoles by removing the benzyl substituent on nitrogen. Exploring the 
debenzylation further, a number of 1,4- and 1,5-disubstituted 1,2,3-triazoles have 
been synthesized and converted exclusively into the corresponding C4-
monosubstituted 1,2,3-triazoles after deprotection provided the substituent on the 
triazole C-atom contains at least one alkoxy group. 
Secondly, a synthetic route for the synthesis of cis and trans 3,4-disubstituted 
piperidine as building blocks for the synthesis of a series of novel piperidines, has 
been developed. Furthermore, trans 3,4-disubstituted piperidine building block has 
been used for the synthesis of 1,4- and 1,5-disubstituted 1,2,3-triazoles as renin 
inhibitors.   
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Introduction 
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31.1 Introduction
1,2,3-Triazoles are nitrogen heteroarenes that have received much attention over the 
past decades and display a range of applications in organic, organometallic, material 
science and combinatorial chemistry as well as agrochemicals.1,2,3 Moreover, 
compounds containing 1,2,3-triazoles are being employed as dyes, corrosion 
inhibitors, photostabilizers and optical brightening agents.4 Not present in natural 
products, their remarkable stability under different severe conditions has triggered 
their utility in a variety of scientific disciplines.5  
The 1,2,3-triazole moiety exhibits structural similarity with the amide bond,6
mimicking a Z or an E amide bond depending on the substitution pattern.7 The 1,4-
disubstituted triazole moiety shows similarity with a Z-amide bond, the lone pair of 
the N(3) mimics the carbonyl oxygen of the amide bond, the C(5)-H bond can show 
intermolecular interactions as a hydrogen bonding donor group,8 like the N-H bond of 
amides, and the electophilic C(5) is electronically similar to carbonyl carbon in amide. 
The overall dipole moment of a triazole system is much stronger than an amide bond,9
but this may actually increase the peptide bond mimicry by enhancing the hydrogen 
bond donor and acceptor properties of triazole.10 Some structural differences between 
triazole and amide bond of course do exist, most notably, the extra atom in the 
triazole backbone leads to an overall increase in R1-R2 distance of 1.1 Å over the 
typical amide bond. While on the other hand the 1,5-substitution pattern mimics the 
E-amide bond. Here, the link between the substituents is identical in terms of atoms 
involved and the relative position of the hydrogen bonding donor and acceptor sites is 
similar as well.11 However, the electrophilic carbonyl carbon is now replaced by a 
negatively polarized nitrogen atom, since there are some differences in atom 
polarization (Figure 1.1). The ability to mimic certain aspects of a peptide bond allow 
41,2,3-triazoles to engage in productive interactions with a variety of other molecules 
including biological targets.5  
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Figure 1.1 Topological and electronic similarities of 1,2,3-triazloes and amides12
Further, molecular modelling has also suggested that a 1,4-disubstituted 1,2,3-triazole 
can mimic the geometry of a ȕ–turn. Indeed, a ȕ-turn was achieved experimentally by 
using two three-carbon linkers in a simple model peptide system13 (see 1, Figure 1.2). 
In the field of peptidomimetics the use of triazoles is further strengthened by a report 
that showed that triazole İ2-amino acids were effective surrogates of dipeptides in Į-
helical structures8 (see 2, Figure 1.2). Similarly, 1,4-disubstituted triazole oligomers 
have been suggested to mimic the structure of  ȕ-strands14 (see 3, Figure 1.2). The 
potential of triazole as an amide bond surrogate in peptidomimetic structures has also 
been evaluated experimentally.     
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Figure 1.2 Examples of peptidomimetic structures 
It has also been predicted that triazoles might act as bioisosteres of the acyl-phosphate 
and trans-olefinic moities, in addition to their potential in mimicking the amide of the 
peptide. During the efforts to prepare inhibitors of enzymes involved in the synthesis 
of siderophores (iron-chelators required for growth and virulence) in Mycobacterium 
tuberculosis, an acyl-phosphate (a good leaving group) was replaced with a stable 
triazole to generate intermediate mimics15 (see 4, Figure 1.3). In resveratrol 
(anticancer and antiaging), the substitution of a trans-olefinic group with a triazole 
moiety16 proved to be more rewarding (see 5, Figure 1.3). This idea was supported by 
molecular modelling that suggested this modification did not alter the spatial 
6arrangements of the phenolic hydroxyls that control the biological activity of this 
phytoalexin (synthesized by plants).  
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Figure 1.3 Triazole as a bioisostere of acylphosphate and trans-olefinic moieties 
The effective 1,4-disubstituted triazole replacement is not limited to above mentioned 
examples, five membered rings containing two nitrogen atoms have been found as 
obvious candidates for bioisosteric substitution with triazoles. As an example of the 
success of this substitution is demonstrated by work on fipronil (an insecticide), a 
library of thirty 1-phenyl-1H-1,2,3-triazole derivatives was synthesised by replacing 
the pyrazole ring with a triazole17 (see 6, Figure 1.4). Interestingly, several 1,4-
regioisomers were found to be more potent competitive inhibitors compared to 
fipronil. Similarly, in carbocyclic nucleosides, derivatives of neplanocin A were 
synthesised replacing the adenine with triazole. In particular, the 1,4-disubstituted 
7triazole derivative 8, that had the most potent antiviral activity against vaccinia virus 
among the five-membered rings tested.18
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Figure 1.4 Triazole as a bioisostere of heterocycles 
Besides the above mentioned potentials of triazoles, they have also been shown to 
possess a number of desirable features in the context of drug delivery and 
nanomedicine. For example, triazoles are stable to acid and basic hydrolysis, severe 
oxidizing and reducing agents, indicative of a high aromatic stabilization. At the same 
time, this moiety can also tolerate a large range of solvents and pH’s and relatively 
resistant to metabolic degradation in living systems.19,20     
The 1,4-disubstituted triazoles are not a novelty in the field of medicinal chemistry. 
Indeed, more than 7000 1,4-disubstituted triazole containing compounds had been 
reported12 well before the recent advances in triazole syntheses (Chapter 2). These 
81,2,3-triazole containing compounds exhibit anti-HIV,21 anti-viral,22 antibacterial,23
anti-inflammatory properties and some compound show selective ȕ3 adrenergic24
receptor inhibition and potent anti-histamine activity25 and more. In antibiotics, 
triazoles have been used to improve pharmacokinetic properties of desired drugs. 
An exciting example of triazole-containing compound is tazobactam, a ȕ-lactamase 
inhibitor, and triazole ring appears to play a pivotal role for its potency.26 Following 
are some of the selected examples12,27,28 of triazole-containing compounds with their 
possible applications (Figure 1.5). 
Figure 1.5 Triazole-containing compounds known before appearance of Cu-catalyzed 
azide-alkyne cycloadditions29
9Recent advances in the syntheses of 1,2,3-triazoles has made them readily accessible 
moieties (Chapter 2) and opened new opportunities in generating a number of 
compounds with biological potential.30,31   
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Figure 1.6 Triazole-containing compounds currently in use 32,33,34
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1.2 Aim of the project 
The aim of this work has been twofold.  
1) We aimed at the synthesis of 1,2,3-triazoles from the highly functionalised 
terminal alkynes encompassing polar substituents. We envisioned that triazoles 
with polar substituents could be useful as peptidomimetics, and that these 
substituents could further be modified. As we have access to two densely 
functionalized terminal alkynes35 (Figure 1.7) we wanted to investigate their 
reactivity towards the synthesis of 1,2,3-triazoles. This is discussed in detail in 
Chapter 2. 
Figure 1.7 Highly functionalized terminal alkynes 
2) The piperidine moiety is an important structural motif in natural alkaloids36
and is a widely used building block, especially in the field of medicinal 
chemistry.37 Preparation of piperidine derivatives is a research field in 
continuous evolution and a number of synthetic methodologies for the 
synthesis of piperidines and their incorporation into more complex structures 
have been developed. Ultimately, a number of functionalized piperidine 
derivatives appear quite frequently in biologically active compounds.38 We 
aimed at the synthesis of a trans-3,4-disubstituted piperidine derivative (Figure 
1.8) and the utilization of this building block for the synthesis of non-peptide 
11
aspartic protease inhibitors containing 1,2,3-triazole substituent in position 4. 
(Figure 1.9) This is discussed in Chapter 3. 
1%RF
25
1
Figure 1.8 Target building block 
Figure 1.9 Target aspartic protease inhibitors  
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Chapter2 
Synthesis of 1,2,3-triazoles 
16
17
2.1. Introduction 
The importance of 1,2,3-triaoles in various scientific fields has resulted in the 
development of several  successful synthetic methodologies for their constructions.1
The most widely used synthetic route involved the thermal 1,3-dipolar [3+2]-
cycloaddition of azides and alkynes investigated by Huisgen and co-workers in the 
1950’s to 1970’s.2,3 The potential of such a thermal cycloadditions is very high as 
alkyne and azide component can be incorporated into a range of substituents.2 In fact, 
due to the kinetic stability of alkynes and azides and usually a weak directing effect of 
substituents, for more than 40 years this reaction suffered from a lack of a selectivity 
producing a mixture of 1,4- and the 1,5-regioisomers (Scheme 2.1).2 Furthermore, 
such reaction requires heating and longer reaction time to go to completion.  
Scheme 2.1 Thermal 1,3-dipolar cycloaddition 4,5
18
A recent discovery, reported independently by Sharpless6 and Meldal7 groups 
described that copper(I) salts were able to accelerate [3+2]-cycloaddition reaction 
between a terminal alkyne and organic azides by up to 107 times,8,9 eliminating the 
need for elevated temperature. More importantly, Cu(I) catalysis dramatically 
improves the regioselectivity to afford the 1,4-regioisomer exclusively with minimal 
work-up and purification.6 This high-yielding reaction tolerates a variety of functional 
groups, converting a very good reaction into the “cream of the crop.”10 However, this 
type of copper catalysis does not promote the cycloadditions of internal alkynes. 
Scheme 2.2 Cu(I)-catalysed [3+2]-cycloaddition11
Since the initial discovery of Cu(I)-catalyzed azide-alkyne coupling, numerous 
examples have been reported, reaction conditions have varied widely, especially with 
respect to generation of the active copper(I) species. Sources of copper(I) include 
Cu(I) salts,7 in-situ reduction of Cu(II) salts6 and comproportionation of Cu(II) and 
Cu(0).12 The improvement of copper-based catalysis is still ongoing at various levels.     
19
Scheme 2.3 Proposed mechanism for Cu(I)-catalysed cycloaddition13
The very success of Cu-catalysed azide-alkyne cycloaddition highlighted the need for 
selective access to the complementary regioisomers, 1,5-disubstituted 1,2,3-triazoles. 
Although, they can be synthesized as prevalent isomers by the action of 
bromomagnesium acetylide with azides (see Section 2.1.4),14 this methodology lacks 
the scope and thereby leads to the loss of versatility. In 2005, Fokin and Sharpless15
reported that the Ru(II)-catalysed approach directs 1,3-dipolar cycloaddition between 
alkynes and azides to afford complimentary regioisomers, the 1,5-disubstituted 1,2,3-
triazoles exclusively (Scheme 2.4). In contrast to the 1,3-dipolar cycloaddtions 
promoted by copper, the ruthenium complex (Cp*RuCl(PPh3)2) was also reported to 
catalysed the cycloaddition reaction of internal alkynes and azides.15  
20
Scheme 2.4 Ru(II)-catalysed [3+2]-cycloaddition 15,16  
Scheme 2.5 Proposed mechanism for Ru(II)-catalysed cycloaddition (Initiall 
coordination of alkyne and azide give intermediate A, oxidative coupling give 
ruthenacycle B or C and reductive elimination leads to product).15,17
21
It is reported in literature that the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddtion 
reactions are not generally affected by the steric and electronic properties of the 
groups close to the reactive centers of azide and alkyne. For example variously 
substituted terminal alkynes usually react well with organic azides carrying a primary, 
secondary, or tertiary group; electron rich or electron deficient group; and aromatic, 
aliphatic or heteroaromatic substituent.13  
While regioselectivity and catalytic efficiency is considerably affected by the nature 
of azide component in Ru-catalyzed 1,3-dipolar cycloaddtion reaction but 
independent of nature of alkyne.15 In [3+2]-cycloadditions of alkyl azide and 
sterically or electronically biased alkynes for the synthesis of 1,4,5-trisubstituted 
1,2,3-triazoles, the regioselectivity is predominantly controlled by the alkyne 
substitution pattern.17  
More than a decade ago, a terminal alkyne with high density of reactive functional 
groups, 3,3,4,4-tetraethoxybut-1-yne (TEB) was prepared in Professor Sydnes 
laboratory.18 Since then this terminal alkyne has been found to be a versatile starting 
material for the synthesis of a range of molecules and its potential to undergo a wide 
range of reactions have been explored to a great extent.19,20,21,22 An important reason 
for this is the presence of high density of reactive functional groups which can 
participate in a number of reactions under various conditions. 
As a part of our recent interest in the synthesis of 1,2,3-triazoles, we decided to 
explore the reactivity and scope of two highly functionalized polar terminal alkynes, 
the ketal 3,3,4,4-tetraethoxybut-1-yne (TEB) and the corresponding ketone 1,1-
diethoxybut-3-yn-2-one (keto-TEB)23 by reacting them with benzyl azide to make 
triazoles. We expected that addition of benzyl azide to TEB and keto-TEB in the 
presence of Cu(I) salt should result in a faster reaction, less by-product formation and 
regioselective formation of 1,4-disubstituted 1,2,3-triazoles, whereas reactions carried 
out in the presence of Ru-catalyst should furnish corresponding 1,5-disubstituted 
analogues only. During this course of study we came across a number of interesting 
results which are discussed in subsequent sections.
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2.1.1 Synthesis of highly functionalized alkynes 
TEB was synthesized in four steps starting from non-acetylenic precursor ethyl vinyl 
ether as shown in Scheme 2.6. 
The synthesis of 1,1-dichloro-2-ethoxycyclopropane (1) by the addition of 
dichlorocarbene to ethyl vinyl ether was a simple straight forward reaction with high 
yield (84%). Under Makosza’s phase-transfer condition,24 chloroform was reacted 
with 50% aqueous sodium hydroxide to generate dichlorocarbene that undergoes 
cyclopropanation with ethyl vinyl ether. The triethylbenzylammonium chloride 
(TEBA) was used as a phase transfer catalyst in this addition reaction.  
The synthesis of 2-chloro-3,3-diethoxyprop-1-ene  (2) from 1 was achieved in 
moderate yield (57%) by thermally induced ring opening reaction using ethanol in the 
presence of pyridine, a method first reported by Skattebøl25 and later modified and 
improved by Kvernenes et al.26  
Using Makosza’s phase-transfer method, the cyclopropanation of 2 was performed to 
generate 1,1-dibromo-2-chloro-2-(diethoxymethyl) cyclopropane (3) in moderate 
yield (56%), where dibromocarbene was produced from a large excess of bromoform. 
The unreacted bromoform is recovered by distillation and recycled. The relatively 
lower yield is attributed to extremely tedious work-up condition due to the formation 
of highly stable emulsion.  
The ring opening reaction of 3 in a mixture of ethanol, 50% aqueous sodium 
hydroxide in the presence of TEBA as phase-transfer catalyst and dichloromethane as 
co-solvent took place smoothly and produced 3,3,4,4-tetraethoxybut-1-yne (TEB) (4) 
as the only product in high yield (85%).  
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The synthesis is simple, reliable and inexpensive since bromoform, the most 
expensive reagent is recycled.  
Scheme 2.6 Four step synthesis of TEB 
The ketal in TEB was hydrolysed under slightly acidic conditions by using Dowex 
50W as acid catalyst in moist acetone to furnish 1,1-diethoxybut-3-yn-2-one (5)23
essentially in quantitative yield (96%) (Scheme 2.7). It has been noticed that older 
batches of Dowex 50W has a weaker catalytic efficiency in deketalization reaction. 
Scheme 2.7 Deketalization of TEB 
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Benzyl azide was prepared by nucleophilic substitution of benzyl bromide using NaN3 
in dimethyl sulfoxide at ambient temperature according to the literature.27  
Scheme 2.8 Synthesis of benzyl azide 
2.1.2 Copper-catalyzed cycloaddition reaction 
The addition of benzyl azide to ketal 4 was first studied. Experiments were first 
carried out in CH3CN, DMF and DMSO in the absence of Cu(I) catalyst at 
temperatures ranging from 60 oC to 110 oC, but cycloadducts were neither isolated nor 
detected. It was surprising because when Sheehan and Robinson reacted polar 
substituent bearing terminal alkyne, 3-phenylprop-2-ynal with phenyl azide an 
approximately 5:2 mixture of the 1,5- and 1,4-diphenyl-1,2,3-triazoles was obtained 
in 90% total yield.28 Similarly, Huisgen and co-workers reported that the reaction of 
methyl propynoate with the same azide under similar conditions produced the 
expected 1,4- and 1,5-disubstituted triazoles in a 7:1 ratio.29 To our surprise the result 
was the same when reactions were performed in aqueous tert-butyl alcohol containing 
Cu(I) generated in situ from copper(II) sulfate and sodium ascorbate, reaction 
conditions commonly used to obtain 1,4-disubstituted 1,2,3-triazoles by azide 
addition.30-6 The outcome was the same when the temperature was raised to 60 oC and 
the solvent was changed to aqueous DMF (Table 1, entry 5). However, when dry 
acetonitrile or mixtures of water with chloroform, dichloromethane or dimethyl 
sulfoxide were used as solvents and CuSO4/sodium ascorbate was applied as catalyst, 
triazole formation took place. The only product formed was 1-benzyl-4-(1,1,2,2-
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tetraethoxyethyl)-1H-1,2,3-triazole (7) (Scheme 2.9) as substantiated by spectroscopic 
data and an X-ray crystallography structure determination (see Figure 2.1 and Table 
2), which revealed that the bond lengths and angles were close to literature values for 
similar compounds.31-35 In all cases the yield was not better than moderate even after 
48 hrs at both room temperature and 60 oC, but generally somewhat higher at the 
higher temperature (Table 1). The rest of the reaction mixture was in essence 
unreacted starting material. 
Scheme 2.9 Cycloaddition under in situ Cu(I)-catalysis  
Table 1 Isolated yield of triazole 7, after 48 hrs at two temperatures 
Entry Solvent Room temperature 60 oC 
1 CH3CN 44% 58% 
2 H2O/CH3Cl (1:3) 41% 51% 
3 H2O/DMSO (1:3) 61% 69% 
4 H2O/CH2Cl2 (1:3) 55% a 
5 H2O/DMF none none 
a The reaction was not run since dichloromethane boils below 60 oC 
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Figure 2.1 Crystal structure of compound 7 
Table 2 Endocyclic bond lengths (Å) and angles (º) for the triazole ring in 736  
Atoms Bond length Atoms Angle 
N(1)-N(2) 1.346(6) N(2)-N(1)-C(5) 111.4(4),
N(1)-C(5) 1.356(7) N(3)-C(4)-C(5) 108.5(5)
 C(4)-N(3) 1.353(7) N(3)-C(4)-C(6) 121.8(4),
C(4)-C(5) 1.382(7) N(3)-N(2)-N(1) 106.6(4),
N(2)-N(3) 1.324(6) N(1)-C(5)-C(4) 104.1(5),
C(5)-H1 0.9500 N(1)-C(5)-H1 128.0
N(2)-N(3)-C(4) 109.4(4).
Crystal system: monoclinic, Density: 1.225 Mg/m3, Volume: 1970.3(12) Å3, Unit cell 
dimentions: a = 6.429(2), b = 41.716(14), c = 7.486(3) Å, Į= 90°, ȕ= 101.092(5)°, Ȗ = 
90° 
N1 
N2 
N3 
C4 C5 
H1 
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An alternative cuprous salt that is often used to facilitate azide-alkyne cycloaddition, 
is copper(I) iodide which is used in the presence or absence of a base.37 When this salt 
was employed instead of CuSO4/sodium ascorbate system, the yield of 7 from 4
generally increased under most conditions, although the best yield (71%, see Table 3) 
was only slightly higher than the best yield obtained with the CuSO4-ascorbate 
catalyst (69%, see Table 1). Again, 1,4-disubstituted 1,2,3-triazole 7 was obtained in 
better yield at 60 oC than at room temperature. Interestingly, no product was detected 
when the reaction was carried out in water mixed with either dichloromethane or 
chloroform (Table 3, entry 4 and 5), an observation which clearly indicates that 
chlorinated solvents for one reason or another prevent triazole formation when CuI is 
used as catalyst. Li et al.38 found that the poor solubility of CuI in halogenated solvent 
retards the cycloaddition reaction. This is not really the case as observed in other 
cycloadditions (Table 4, entry 9 and 10). Another notable feature is the consistent 
formation of an additional, minor product, which finally turned out to be 1-benzyl-5-
iodo-4-(1,1,2,2-tetraethoxyethyl)-1H-1,2,3-triazole (8) as additionally confirmed by 
an independent known synthetic route (Scheme 2.11).
Scheme 2.10 Cycloaddition with CuI as catalyst 
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Table 3 Isolated yields of triazole 7 and 5-iodotriazole 8 after 48 hrs  
Room temperature 60 oC 
Entry Solvent 
7                       8 7                       8
1 
2 
3 
CH3CN 
H2O/DMSO (1:3) 
H2O/DMF (1:3) 
68%                   6% 
69%                   3% 
42%                   5% 
71%                   5% 
61%                   3% 
62%                   7% 
4 H2O/CH2Cl2 none None 
5 H2O/CH3Cl none None 
The yield of 8 was very low when CuI was applied in the absence of base (< 7%, see 
Table 3), but when the reaction was performed with CuI in the presence of 
diisopropylethylamine (DIPEA) and either N-chlorosuccinimide (NCS) or N-
bromosuccinimide (NBS) as electrophilic iodinating reagents,38 triazole 7 was not 
formed whereas 5-iodotriazole 8 was obtained in a respectable yield (72% and 62% 
yield, respectively) (Scheme 2.11). 
Scheme 2.11 Synthesis of 5-Iodo-isomer 
Copper-catalyzed addition of benzyl azide to ketoalkyne 5 was then performed. On 
the basis of a paper published by Girard et al.39 who studied the addition of the same 
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azide to various alkynes containing polar substituents under similar conditions, we 
expected regiospecific formation of the analogous 1,4-disubstituted 1,2,3-triazole in 
moderate to good yield. That was indeed observed when CuSO4/sodium ascorbate 
was used as catalyst system (Table 4); the only product obtained, in up to 70% yield 
(entry 5), was 1-(1-benzyl-1H-1,2,3-triazole-4-yl)-2,2-diethoxyethanone (9), which 
structure was elucidated by spectroscopic analyses and finally also unequivocally 
substantiated by a high-yield (90%) independent synthesis through deketalization of 7
(Scheme 2.13). 
Scheme 2.12 Cycloaddition of ketoalkyne and benzyl azide 
When addition of benzyl azide to keto-TEB 5 was carried out under CuI catalysis, the 
outcome of the reaction changed somewhat. 1,4-Disubstituted triazole 9 was still the 
predominant product (Table 4, entry 6), but in addition the corresponding 1,5-
disubstituted isomer, viz. 1-(1-benzyl-1H-1,2,3-triazole-5-yl)-2,2-diethoxyethanone 
(10), was obtained (Scheme 2.14) in up to 10% yield (Table 4, entry 8). Furthermore, 
unlike TEB 4 the corresponding ketone 5 appeared not to furnish any iodotriazole, 
and by analyzing the crude reaction mixture with respect to the iodoketo 
corresponding to iodoketal 8, viz. 1-(1-benzyl-5-iodo-1H-1,2,3-triazole-4-yl)-2,2-
diethoxyethanone (11) prepared by deketalization of 8 (Scheme 2.15), it was 
unambiguously proved that iodide 11 was not formed under the conditions that 
furnished 8 from 4. 
30
Table 4 Isolated yields of triazoles 9 and 10 in 48 hr. 
Room temperature 60 oC 
Entry Catalyst Solvent 9                  10 9              10 
1 
2 
3 
4 
5 
CuSO4/Ascorbate CH3CN 
H2O/DMSO (1:3) 
H2O/DMF (1:3) 
H2O/CH3Cl (1:3) 
H2O/CH2Cl2 (1:3) 
   59%                
   61%                
   51%                
   48%                
   70%                
    61%          
    69%          
    60%          
    52%           
a 
6 
7 
8 
9 
10 
CuI CH3CN 
H2O/DMSO (1:3) 
H2O/DMF (1:3) 
H2O/CH3Cl (1:3) 
H2O/CH2Cl2 (1:3) 
   61%               3% 
   54%               3% 
   52%              10% 
   58%               3% 
   59%               0% 
    70%         3% 
    61%         2% 
    61%         4% 
    54%          5% 
a 
a The reaction was not run since dichloromethane boils below 60 oC. 
Scheme 2.13 Deketalization reaction  
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Scheme 2.14 Cycloaddition with CuI as catalyst 
Scheme 2.15 Deketalization reaction of 5-I-triazole 
It is concluded that the reactivity exhibited by TEB 4 and keto-TEB 5 is essentially 
identical when the CuSO4/sodium ascorbate catalyst system is applied, and this 
indicates that, under these conditions, the cycloaddition is barely sensitive to the 
functional groups’ different ability to both conjugate with the neighbouring C-C triple 
bond and form complexes with the copper species involved in reaction. However, 
when CuI is the catalyst one similarity and two differences are observed. The 
similarity is that both alkynes give the corresponding 1,4-disubstituted 1,2,3-triazole 
as the main product (60-70% yield) along with one by-product (typically in 3-7% 
yield). The differences are the structures of the by-products produced in the two 
cases; whereas the by-product in the case of acetylenic ketal 4 is the 5-iodinated 
derivative of the main product, the by-product from acetylenic ketone 5 is the iodine-
free 1,5-disubstituted structural isomer of the main product. 
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2.1.3 Ruthenium-catalyzed cycloadditions 
The formation of 1,5-disubstituted triazole 10 as a by-product when keto-TEB 5 was 
reacted with benzyl azide in the presence of CuI indicates that 10 might be formed in 
higher yields if the reaction is carried out under conditions that are known to favour 
1,5-disubstituted-1,2,3-triazole formation over 1,4-disubstituted-1,2,3-triazole 
formation in such addition reactions. In order to favour dominance of the former 
Cu(I) salt was replaced by a ruthenium complex, bis(triphenylphosphine) 
pentamethylcyclopentadienyl ruthenium(II) chloride (Cp*RuCl(PPh3)2) and reactions 
were performed in THF and benzene.15 After having run the reaction between benzyl 
azide and phenylacetylene under Cp*RuCl(PPh3)2 catalysis several times as described 
in the literature and obtained 1-benzyl-5-phenyl-1,2,3-triazole (12) as the only product 
in consistently better than 85% yield (Table 5, entry 1) ketal 4 was reacted with 
benzyl azide under the same conditions (Scheme 2.16). To our surprise no reaction 
occurred as observed from chromatographic and spectroscopic analyses, and when the 
reaction mixture was worked up in the usual way, both reactants were recovered in 
high yield (Table 5, entries 2 and 3).  
Scheme 2.16 Cycloaddition for 1,5-disubstituted 1,2,3-triazole
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Table 5 Outcome of syntheses performed to obtain 1,5-disubstituted 1,2,3-triazoles 
Entry Alkyne Reaction conditions Isolated compounds (yield) 
1 Cp*RuCl(PPh3)2, THF, 65 ºC, 3 h 12 (86%) 
2 4 Cp*RuCl(PPh3)2, THF, 65 ºC, 24 h 4 (95%) and 6 (96%) 
3 Cp*RuCl(PPh3)2, C6H6, 80 ºC, 24 h 4 (94%) and 6 (93%) 
4 5 Cp*RuCl(PPh3)2, THF, 65 ºC, 4 h 13 (55%) and 6 (91%) 
5  Cp*RuCl(PPh3)2, C6H6, 80 ºC, 3 h 13 (60%) and 6 (88%) 
When the substrate was changed to keto-TEB 5, TLC analysis showed that a reaction 
took place. Subsequent work-up revealed that all of 5 had been consumed and been 
converted to one product which appeared not to be a triazole, but 1,3,5-tris(2,2-
diethoxyacetyl)benzene (13) that was obtained in 55% and 60% yield at 65 oC and 80 
oC, respectively (Table 5, entries 4 and 5). This trimer of 5 has previously been 
obtained by treating 5 with aqueous solutions of sodium bicarbonate.40 The formation 
of 13 is not really surprising because ruthenium complexes have proved to facilitate 
cyclotrimerization of electron-deficient alkynes 41, 42,42 (also see Section 2.3). The 
mechanism for the reaction has not been unraveled, but a suggestion is depicted in 
Scheme 2.17. 
Figure 2.2 Trimer produced in Ru-catalyzed reaction 
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Scheme 2.17 A proposed mechanism for the formation of 13 Nu - denotes an 
unknown nucleophilic species derived from Cp*RuCl(PPh3)2. 
Thus, the different behaviour of TEB and Keto-TEB toward Cp*RuCl(PPh3)2 is quite 
likely due to increased reactivity associated with conjugative effects between the 
triple bond and the carbonyl group, but it cannot be ruled out that when TEB is 
reacted, the catalyst is so much deactivated by some sort of complexation with some 
or all of the four oxygen atoms in the tetraethoxyethyl moiety that TEB is rendered 
unreactive even after 24 hr.  
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2.1.4 1,5-Disubstituted 1,2,3-triazoles via addition of 
bromomagnesium acetylides to azides 
Regioselective synthesis of 1,5-disubstituted 1,2,3-triazoles from terminal alkynes has 
also been achieved by adding bromomagnesium acetylides to organic azides.43,14 The 
proposed mechanism begins with the nucleophilic attack of acetylide on terminal 
nitrogen atom of the azide, followed by spontaneous closure of the intermediate to 4-
metallotriazole which after hydolysis gives triazole 
Scheme 2.18 Proposed mechanism for synthesis of 1,5-disubstituted 1,2,3-triazoles14
After having conducted the reaction between benzyl azide and the acetylide from 
phenylacetylene14 several times and isolated 1-benzyl-5-phenyl-1,2,3-triazole (12) as 
the only product in 93% yield the acetylide from TEB 4 was reacted with benzyl azide 
in exactly the same way (Scheme 2.19). To our disappointment the reaction failed to 
generate any 1,2,3-triazole; instead both benzyl azide and TEB 4 were recovered in 
almost quantitative (98% TEB and 97% BnAz) yield even after 24 hr (Table 6). 
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Scheme 2.19 Addition of halomagnesium acetylides to azide 
Table 6 1,5-disubstituted 1,2,3-triazoles via addition of halomagnesium acetylides 
Entry R Reaction conditions (%yield) 
1 Ph EtMgBr, THF, NH4Cl, 50 ºC (12) 93% 
2 C(OEt)2CH(OEt)2 EtMgBr, THF, NH4Cl, 50 ºC - 
3 C(OEt)2CH(OEt)2 EtMgCl, THF, NH4Cl, 50 ºC - 
37
2.2 Debenzylation of N-benzyl 4- and 5-substituted 1,2,3-triazles 
The benzyl group has found wide applications as a protecting group for amines and 
N-debenzylation is an important conversion for the deprotection. The Pd-C catalyzed 
hydrogenolysis is one of the most studied reactions for N-debenzylation of 
benzylamines. This reaction is however normally found to occur for basic 
compounds. In addition to some reasonably described methodologies,44,45,46 N-
unsubstituted, i.e NH-1,2,3-triazoles can also be prepared by hydrogenolysis of N-
benzylsubstituted 1,2,3-triazoles in the presence of palladium on carbon. A report by 
Wiley et al.47 on the use of the benzyl group as a N-protecting group for the synthesis 
of 1,2,3-triazoles describes the requirement for an elevated temperature and high 
hydrogen pressure for the debenzylation of 1-benzyl-4,5-disubstituted-1,2,3-triazoles. 
However, another report suggests the use of atmospheric hydrogen pressure to 
facilitate the removal of a N-benzyl group from C4- or C5-mono substituted or 4,5-
disubstituted 1,2,3-triazoles.48
We found that N-benzylsubstituted 1,2,3-triazole 7 could be debenzylated by catalytic 
hydrogenolysis over 10% Pd-C in methanol for 24 hr to provide 4-(1,1,2,2-
tetraethoxyethyl)-1H-1,2,3-triazole (14) in 95% yield (Scheme 2.20).  
Scheme 2.20 Debenzylation of triazole 7
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According to the literature reports, hydrogenolysis of benzylamines can be facilitated 
by the addition of hydrochloric acid to protonate the amine.49 Keeping this in view, 
when the previous reaction (Scheme 2.20) was repeated with the addition of two 
drops of concentrated HCl, the ketal functionality was converted to the ketone, giving 
9 (64%) and a red-brown polymeric material after 24 hrs and no debenzylation was 
observed.  
A novel procedure recently developed by Cheng et al. describes the accelerated 
hydrogenolysis of benzylamines by HCl released in situ in the hydrodechlorination of 
1,1,2-trichloroethane.50 Following this protocol, 1,2,3-triazole 7 was completely 
debenzylated after only two hours to produce the NH-1,2,3-triazole 14 in 97% yield. 
This increase in the rate of the reaction prompted us to explore whether other 
substituted 1-benzyl 1,2,3-triazoles could be debenzylated following this protocol.  
Towards this end, a number of 1,4-disubstituted 1,2,3-triazoles were synthesized by 
copper-catalyzed addition of benzyl azide to various alkynes and CuSO4/sodium 
ascorbate was used as catalyst system while corresponding 1,5-disubstituted 1,2,3-
triazoles were prepared by Ru(II)-catalysis using Cp*RuCl(PPh3)2 in THF or C6H6 as 
described in previous sections.51 The reaction times and yields for the individual 
triazole syntheses are summarized in Table 7. As previously discussed, 1,5-
disubstituted 1,2,3-triazoles from alkyne 4 and 5 were not formed at all (Section 2.1)
and Ru-catalyzed reaction between methyl propiolate and benzyl azide produced a 
fraction of 15b along with trimethyl benzene-1,3,5-tricarboxylate (15c) (Figure 2.3).  
Figure 2.3 Trimer of methyl propiolate 15c
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Scheme 2.21 Synthesis of 1,4-and 1,5-disubstituted 1,2,3-triazoles 
Table 7 1,4-and 1,5-disubstituted 1,2,3-triazoles from various alkynes 
1,4-isomera 1,5-isomerb 
Entry R 
Triazole
(%) 
Yield 
Time 
(hr) 
Triazole
(%) 
Yield 
Time 
(hr) 
1 CH3OCO 15a 99 12 15b 3 4 
2 Ph 12a 99 12 12 86 3 
3 PhCH2 16a 95 12 16b - - 
4 CH3OCH2 17a 99 20 17b 76 4 
5 PhOCH2 18a 95 12 18b 97 4 
6 CH(OEt)2 19a 98 12 19b 79 4 
7 CH3CHOH 20a 97 24 20b 42-70 3 
Conditions: a) CH2Cl2/H2O (3:1) and CuSO4/sodium ascorbate; b) Cp*RuCl(PPh3)2,C6H6 at 
80 ºC or in THF at 65 ºC 
While 1,4-disubstituted 1,2,3-triazole 7 was cleanly debenzylated to give 14, the 
1,2,3-triazole 9 underwent a reduction in addition to the debenzylation, to give the 
secondary alcohol, 2,2-diethoxy-1-(1H-1,2,3-triazol-4-yl)ethanol (21) in high yield 
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(Table 8). Direct debenzylation of 1-(1-benzyl-1H-1,2,3-triazol-4-yl)-2,2-
diethoxyethanol (22), prepared by NaBH4-mediated reduction of 9 (Scheme 2.22), 
afforded 21 in 97% isolated yield after 9 hr reaction time (Table 8, entry 2). However, 
the expected ketone, 2,2-diethoxy-1-(1H-1,2,3-triazol-4-yl)ethanone (23) from 1,2,3-
triazole 9 was alternatively synthesized by the deketalization of 14 in high yield 
(93%) in 6 hr (Scheme 2.23). 
Scheme 2.22 Reduction of triazole 9 
Scheme 2.23 Deketalization of NH-1,2,3-triazole 14 
Scheme 2.24 N-debenzylation of 1,4- and 1,5-disubstituted 1,2,3-triazoles 
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Table 8 Debenzylation of 1,2,3-triazolesa 
Entry Substrate Time (h) Yield (%) Product 
1 7 2 97 
2 9 24 85 
22 9 97 
3 15a 36 96 
4 12a 24 no reaction 
5 12 24 no reaction 
6 16a 24 no reaction 
7 17a 28 95 
17b 21 94 
8 18a 24 30 
18b 24 94 
9 19a 24 94 
19b 24 94 
10 20a 24 96 
20b 24 94 
a) Conditions: 10% Pd-C, ClCH2CHCl2, MeOH, r.t.  
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Further, hydrogenolysis of the 1,4-isomer 15a equipped with methoxy carbonyl 
substitutent gave 97% of debenzylated product in 36 hr (Table 8 , entry 3). However, 
when 1,4-disubstituted 1,2,3-triazole 12a, 16a and 1,5-disubstituted 1,2,3-triazole 12
were submitted to debenzylation conditions, to our surprise no reaction occurred even 
after 24 hr and starting material could be recovered in 95% yield in all cases (Table 
11). Contrary to this, the 1,4- and 1,5-disubstituted 1,2,3-triazoles 17a and 17b were 
both readily debenzylated in 28 and 21 hr respectively (Table 8, entry 7) and the 
analytical data of products obtained from both isomers were identical in all respects. 
Which suggested the formation of only one isomer of NH-1,2,3-triazole either C4- or 
C5-substituted. Whereas, Yap and Weinreb52 in 2006 has reported that TSE-protected 
1,4- and 1,5-disubstituted 1,2,3-triazole produced C4- and C5-monosubstituted NH-
1,2,3-triazle respectively after removing the TSE-protecting group under mildly basic 
conditions via a retro-Michael reaction (Scheme 2.25). This fact was not in consistent 
with our results.  
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Scheme 2.25 Removal of TSE-protecting group by Yap and Wienreb52
According to Dabbagh et al.53 the C-monosubstituted 1,2,3-triazole exhibits 
tautomerism: the (N)H hydrogen atom can be attached to the 1st, 2nd or 3rd nitrogen 
atom. For C-monosubstituted NH-1,2,3-triazoles, the N1-H-C4 tautomer (Figure 2.4) 
is generally described as being more stable than the N3-H-C5 tautomer, with the N2-
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H being the most stable tautomer. It has also been suggested that the relative stability 
of the C5-substituted 1,2,3-triazloe tautomerism is strongly influenced by 
intramolecular interactions between substituent and protons located either at N1 or N3 
atom. The nature of substituent, electron withdrawing or donating and possibility of 
hydrogen bonding play an important role in this regard.54
Figure 2.4 Tautomers of C-monosubstituted NH-1,2,3-triazoles. 
Based on experimental and theoretical studies, Abboud et al.55 reported that in gas 
phase, 2H tautomers b always predominates, while in aquous solution, both 1H and 
2H tautomers- a and b are present equally. In solid state C-monosubstituted NH-1,2,3-
triazoles can be a or b with an equal probability (Figure 2.5). 
Figure 2.5 Tautomers of NH-1,2,3-triazoles. 
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Under debenzylation conditions, the conversion of triazole 18a was low, most likely 
due to its low solubility in methanol, and only 30% of 4-(phenoxymethyl)-1H-1,2,3-
triazole (18c) could be isolated even after 24 hr reaction time (confirmed by GC-MS) 
and 39% in 48 hr when reaction was run in ethanol. Interestingly, the C5-substituted 
isomer 18b was fully converted to 18c under identical conditions in 24 hr reaction 
time. We were also able to obtain a single crystal X-ray structure from 18c (Figure 
2.6). In the solid state an intermolecular hydrogen bond with the triazole NH as the 
donor and a triazole N(2) as the acceptor, was observed. The hydrogen bond length 
was measured to 2.1 Å with an N-H-N angle of 148.4 º. From the crystal structure it is 
clear that for the present case, the N1-H-C4 tautomer (see Figure 2.4) is the preferred 
tautomer in the solid phase. The N1-N2-N3 bond angle was found to be 107.8 º,  
which is typical for this tautomeric form.55 However, for the N2-H tautomer, this 
bond angle is typically found to be around 116 º. 
Figure 2.6 Single crystal structure of 18c with intermolecular hydrogen bonding. 
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Table 9 Endocyclic bond lengths (Å) and angles (º) for the triazole ring in 18c56
Atoms Bond length Atoms Angle 
N(1)-N(2) 1.338 N(2)-N(1)-C(5) 110.75
N(1)-C(5) 1.342 N(3)-C(4)-C(5) 108.58
 C(4)-N(3) 1.365 N(3)-C(4)-C(6) 121.32
C(4)-C(5) 1.365 N(3)-N(2)-N(1) 107.76
N(2)-N(3) 1.324 N(1)-C(5)-C(4) 105.12
C(5)-H(2) 0.974 N(1)-C(5)-H2 123.37
N(1)-H(1) 0.877 N(2)-N(3)-C(4) 107.78
C(5)-N(1)-H(1) 127.71 
Unit cell dimentions: a = 14.227 (10), b = 5.348 (4), c = 11.087 (8) Å, Į= 90°, ȕ= 
92.437 (8)°, Ȗ = 90°  (The bond length and angles have been compared with literature 
values).55,53,33, 57
In line with the reactivity described so far, the C4-alkoxy substituted 19a and C5-
alkoxy substituted 19b were efficiently debenzylated to a NH-1,2,3-triazole in 
excellent yield (Table 8, entry 9), but interestingly the ethoxy groups were replaced 
with methoxy groups giving 4-(diethoxymethyl)-1H-1,2,3-triazole (24) instead of 19c
as the product. The progress of this reaction was followed by GC-MS; it was found 
that the exchange of alkoxy groups and debenzylation occurred at the same time as 
only two peaks were present in the chromatogram; one reactant peak with ethoxy 
groups (at 27.95 min) and one product peak with methoxy groups (at 14.49 min) 
(Figure 2.7).  
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Figure 2.7 GC-chromatogram of debenzylation of 19b after 8 hr 
Further, it was found that 24 was unstable as it was converted into 1H-1,2,3-triazole-
4-carbaldehyde (25) upon standing in the fume hood for few days (see Experimental 
section). 
In 2003 OzimiĔski et al.54 reported on the basis of DFT studies that the electron 
withdrawing or donating effect of substituent at position C5(4) is not the only  
intramolecular effect that stabilize the 1,2,3-triazole ring. Indeed, the possibility for 
intramolecular interactions (both repulsive and attractive) between substituent and 
proton present either at N1 or N3 atom play vital role in tautomer stabilization.  
47
1 11+
+
2
+
1 11+
+
+
2
11 1
+
2
+
11 1
2
+
+
1 1 1
+
2
+
+ +
+
1 1 1
2
+
+
+
 
 


 

 
   

 
 
 
Figure 2.8 5-aldo-1,2,3-triazoles on rotation of –CHO substituent54
In the above case (Figure 2.8), from DFT calculations the most stable form appeared 
to be that with an intramolecular hydrogen bond present in the system, in gas phase: 
the C-H or C=O moieties of aldehyde group with the N1 or N1-H moiety of triazole 
ring (structure 3). However, in our case, the x-ray analysis of a single crystal of 25 
revealed that also for this monosubstituted 1,2,3-triazole the N1-H-C4 tautomer is the 
most stable in the solid phase (Figure 2.9). In this case, the N1-N2-N3 bond angle was 
also found to be 106.9º, typical for N1-H-C4 tautomer. The intermolecular hydrogen 
bonding was evident also for this crystal structure. In this case, the triazole NH forms 
hydrogen bonds with both the N3 and the carbonyl oxygen atom acting as hydrogen 
bond acceptors. The bond lengths were measured to 2.3 Å and 2.2 Å for the the O-H 
and N-H bonds respectively with N-H-N and N-H-O bond angles of 141.8 Å and 
139.3 Å respectively. 
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Figure 2.9 X-ray crystal structure of 25 
Table 10 Endocyclic bond lengths (Å) and angles (º) for the triazole ring in 2558
Atoms Bond length Atoms Angle 
N(1)-N(2) 1.350 N(2)-N(1)-C(5) 111.34 
N(1)-C(5) 1.338 N(3)-C(4)-C(5) 108.49 
 C(4)-N(3) 1.369 N(3)-N(2)-N(1) 106.92 
C(4)-C(5) 1.362 N(1)-C(5)-C(4) 104.53 
N(2)-N(3) 1.303 N(1)-C(5)-H 127.77 
C(5)-H(2) 0.950 N(2)-N(3)-C(4) 108.72 
N(1)-H(1) 0.880 C(5)-N(1)-H(1) 124.30 
Crystal system: monoclinic, Density: 1.573 Mg/m3, Volume: 205.0(10) Å3, Unit cell 
dimentions: a = 3.6581(10), b = 10.204(3), c = 5.4918(16) Å, Į= 90°, ȕ= 90.154(3)°, 
Ȗ = 90° (The bond length and angles have been compared with literature 
values).55,53,33, 57 
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In order to avoid the replacement of ethoxy groups in methanol, the debenzylation 
reaction of 19a was repeated using ethanol as the solvent, a clean conversion to 19c
was observed in 12 hr (Scheme 2.26). However, debenzylation reaction produced 19c
in near quantitative yield in 62 and 68 hr when 19a and 19b were submitted to 
debenylation in ethanol in the absence of trichloroethane (Scheme 2.27).    
Scheme 2.26 Debenzylation of 19a in ethanol  
Scheme 2.27 Debenzylation in ethanol without trichloroethane 
The conversion of 17a, 17b, 19b in methanol and 19a in ethanol to their 
corresponding NH-1,2,3-triazoles have been studied on GC-MS (Figure 2.10). These 
reactions found to be very slow in first 10 hr (less than 15% conversion) except the 
conversion of 19a which is completed in 12 hr, faster than any other. However, 19a
completed its conversion in 24 hr when reaction was run in methanol (not shown in 
Figure 2.10). 
50
Synthesis of NH-1,2,3-triazoles
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Figure 2.10 Synthesis of NH-1,2,3-triazoles studied on GC-MS 
Since both the 1,4- and 1,5-disubstituted 1,2,3-triazoles were found to be susceptible 
to the debenzylation reaction, as long as the C4/C5-substituent contained oxygen 
atoms, we were interested to see if this was also the case for 4,5-disubstituted 1-
benzyl 1,2,3-triazoles. Thus, 1-benzyl-4,5-bis(methoxymethyl)-1H-1,2,3-triazole (26), 
which has the same C4/C5-substituent as 17a and 17b was prepared from 1,4-
dimethoxybut-2-yne and benzyl azide using Cp*RuCl(PPh3)2 as the catalyst in 
refluxing benzene (Scheme 2.28) 
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Scheme 2.28 Synthesis of 4,5-disubstituted 1-benzyl 1,2,3-triazole 
To our dismay, the 1,4,5-trisubstituted 1,2,3-triazole 26, did not undergo a 
debenzylation reaction during 24 hr, and the starting material could be recovered in 
near quantitative yield (Table 11).  
In an earlier account in 2008, Kalsiaki et al.59 found that triazole 27 could be 
converted to the corresponding NH-1,2,3-triazole through simple hydrogenation using 
10% Pd-C in MeOH. However, this sluggish reaction required 7 days to go to 
completion. We consider that trichloroethane also for this reaction could act as an 
accelerant, and for this very purpose 1,2,3-triazole 27, 28 and 29 were prepared to 
explore it further.  
The required organic azide was prepared from benzyl chloromethyl ether following 
the procedure described in literature. Similarly, 1,4- disubstituted 1,2,3-triazoles 27, 
29 and the 1,5-disubstituted 1,2,3-triazole 28 were synthesized according to the 
previously described Cu(I) and Ru(II)-catalysis (Figure 2.11). Interestingly, it was 
observed that N-alkoxy substituted triazoles 27, 28 and 29 were not converted to NH-
1,2,3-triazoles after submission to the debenzylation conditions for 24 hr and in all 
cases the starting materials could be recovered in near quantitative yield (Table 11). 
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Figure 2.11 Synthesis of N-Alkoxy substituted 1,2,3-triazoles 
Table 11 1,2,3-Triazoles which did not undergo debenzylation.  
Entry Substrate (%) St. material recovered Time (h)
1 12a 95 24 
2 12 96 24 
3 16a 98 24 
4 26 98 24 
5 27 98 24 
6 28 98 24 
7 29 98 24 
It is concluded that C4-monosubstituted NH-1,2,3-triazoles can be obtained from 4- 
and 5-substituted 1-benzyl 1,2,3-triazoles in excellent yields by hydrogenation over 
10% Pd-C and 1,1,2-trichloroethane in methanol provided the substituent on the 
triazole C-atom contains at least one alkoxy group.
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2.3 Summery 
It has been observed that the cycloaddions of benzyl azide to highly functionalized 
terminal alkynes under Cu(I)-catalysis and Ru(II)-catalysis are largely influenced in 
terms of regioselectivity and efficacy by the nature of alkyne, substitution next to the 
C-C triple bond is important in this regard as observed from the reactivity of alkyne 4
and 5.       
Similarly, synthesis of C4-monosubstituted NH-1,2,3-triazoles by the debenzylation 
of 4- and 5-substituted 1-benzyl 1,2,3-triazoles found to be dependent on the presence 
of alkoxy group on C4 or C5 of the triazole ring but independent of the presence of 
alkoxy group on N-atom. It is found that the HCl driven hydrogenolysis is facilited by 
the alkoxy group at C4 or C5 in 1-benzyl 1,2,3-triazoles. Further, alkoxy group at C4 
or C5 also helps to stabilize C4-alkoxy substituted NH-1,2,3-triazole tautomer.  
54
Reference 
1. Tome, A. C., Science of Synthesis. Thieme New York, 2004; Vol. 13, p 415-
601. 
2. Huisgen, R., 1,3-Dipolar Cycloaddition Chemistry. Wiley: New York, 1984; p 
1. 
3. Huisgen, R., Journal of Pure and Applied Chemistry 1989,  (61). 
4. Kitamura, Y.; Taniguchi, K.; Maegawa, T.; Monguchi, Y.; Kitade, Y.; Sajiki, 
H., Heterocycles 2009, 77, 521. 
5. Cabrero-Antonino, J. R.; Garcia, T.; Rubio-Marques, P.; Vidal-Moya, J. A.; 
Leyva-Perez, A.; Al-Deyab, S. S.; Al-Resayes, S. I.; Diaz, U.; Corma, A., ACS Catal. 
2011, 1, 147. 
6. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B., Angew. Chem. 
Int. Ed. 2002,  (41), 2596. 
7. Tornøe, C. W.; Christensen, C.; Meldal, M., J. Org. Chem. 2002, 67 (9), 3057. 
8. Appukkuttan, P.; Dehaen, W.; Fokin, V. V.; Van der Eycken, E., Org. Lett. 
2004, 6 (23), 4223. 
9. Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V.; Noodleman, L.; Sharpless, 
K. B.; Fokin, V. V., J. Am. Chem. Soc. 2004, 127 (1), 210. 
10. Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Angew. Chem. Int. Ed. 2001, 40
(11), 2004. 
11. Hagiwara, H. Reclaimable azide-alkyne cycloaddition catalysts and preparation 
of triazole compounds therewith. JP2009178612A, 2009. 
12. Wang, Q.; Chan, T. R.; Hilgraf, R.; Fokin, V. V.; Sharpless, K. B.; Finn, M. 
G., J. Am. Chem. Soc. 2003, 125 (11), 3192. 
13. Wu, P.; Fokin, V. V., Aldrichimica Acta 2007, 40 (1), 7. 
14. KrasiĔski, A.; Fokin, V. V.; Sharpless, K. B., Org. Lett. 2004, 6 (8). 
15. Zhang, L.; Chen, X.; Xue, P.; Sun, H. H. Y.; Williams, I. D.; Sharpless, K. B.; 
Fokin, V. V.; Jia, G., J. Am. Chem. Soc. 2005, 127 (46), 15998. 
16. Farooq, T.; Haug, B. E.; Sydnes, L. K., Manuscript 2012. 
17. Majireck, M. M.; Weinreb, S. M., J. Org. Chem. 2006, 71, 8680. 
18. Sydnes, L. K., Eur. J. Org. Chem. 2000, 3511 
19. Kvernenes, O. H.; Sydnes, L. K., Org. Synth. 2006, 83, 184. 
20. Sydnes, L. K.; Holmelid, B.; S, M.; Hanstein, M., J. Org. Chem. 2009,  (74), 
3430. 
21. Sydnes, L. K.; Holmelid, B.; Kvernenes, O. H.; Sandberg, M.; Honde, M.; 
Bakstad, E., Tetrahedron 2007,  (63), 4144. 
22. Holmelid, B.; Kvernenes, O. H.; Hodne, M.; Sydnes, L. K., ARKIVOC 2008,
v1, 26. 
55
23. Sydnes, L. K.; Kvernenes, O. H.; Valdersnes, S., Pure Appl. Chem. 2005,  (77), 
119. 
24. Ma ޽kosza, M.; Wawrzyniewicz, M., Tetrahedron Lett. 1969, 10 (53), 4659. 
25. Skattebøl, L., J. Org. Chem. 1966, 31, 1554. 
26. Kvernenes, O. H. 3,3,4,4-Tetraethoxybut-1-yne and analogues as synthons in 
organic synthesis. University of Bergen, Norway, 2005. 
27. Alvarez, S. G.; Alvarez, M. T., Synthesis 1997, 1997 (04), 413. 
28. Sheehan, J. C.; Robinson, C. A., J. Am. Chem. Soc. 1951, 73 (3), 1207. 
29. Huisgen, R.; Knorr, R.; Moebius, L.; Szeimies, G., Chem. Ber. 1965, 98, 4014. 
30. Shehan, J. C.; Robinson, C. A., J. Am. Chem. Soc. 1949,  (71), 1436. 
31. Soetofte, I.; Nielsen, K., Acta chem. Scand., Ser. A 1984, A38 (6), 497. 
32. Nielsen, K.; Søtofte, I., Acta Chem. Scand. 1979, A 33, 697. 
33. Nielsen, K.; Søtofte, I., Acta Chem. Scand. 1985, A 39, 259. 
34. Kálmán, A.; Argay, G., J. Mole. Struct. 1983, 102 (3–4), 391. 
35. Domnin, I.; Remizova, L.; Starova, G.; Rominger, F., Russ. J. Org. Chem. 
2009, 45 (11), 1678. 
36. CCDC 811697 contains the supplementary crystallographic data for 7. These 
data can be obtained free of charge on application to CCDC, 12 Union Road, 
Cambridge, CB2 IEZ, UK e-mail: deposit@ccdc.cam.ac.uk.     
37. Cohrt, A. E.; Jensen, J. F.; Nielsen, T. E., Org. Lett. 2010,  (12), 5414. 
38. Li, L.; Zhang, G.; Zhu, A.; Zhang, L., J. Org. Chem. 2008,  (73), 3630. 
39. Girard, C.; Oenen, E.; Aufort, M.; Beauvière, S.; Samson, E.; Herscovici, J., 
Org. Lett. 2006,  (8), 1689. 
40. Sengee, M.; Sydnes, L. K., Synthesis 2011, 23, 3899. 
41. Kirchner, K.; Calhorda, M. J.; Schmid, R.; Veiros, L. F., J. Am. Chem. Soc. 
2003, 125 (38), 11721. 
42. Yamamoto, Y.; Arakawa, T.; Ogawa, R.; Itoh, K., J. Am. Chem. Soc. 2003,
125 (40), 12143. 
43. Odlo, K.; Hentzen, J.; dit Chabert, J. F.; Ducki, S.; Gani, O. A. B. S. M.; Sylte, 
I.; Skrede, M.; Flørenes, V. A.; Hansen, T. V., Bioorg. Med. Chem. 2008, 16 (9), 
4829. 
44. Kamijo, S.; Jin, T.; Huo, Z.; Yamamoto, Y., J. Am. Chem. Soc. 2003, 125 (26), 
7786. 
45. Looker, J. J., J. Org. Chem. 1965, 30 (2), 638. 
46. Loren, J. C.; KrasiĔski, A.; Fokin, V. V.; Sharpless, K. B., Synlett 2005, 2005
(EFirst), 2847. 
47. Wiley, R. H.; Hussung, K. F.; Moffat, J., J. Org. Chem. 1956, 21 (2), 190. 
48. Pati, Heterocycl. Commun. 2005, 11 (2), 117. 
49. Evans, G. B.; Furneaux, R. H.; Greatrex, B.; Murkin, A. S.; Schramm, V. L.; 
Tyler, P. C., J. Med. Chem. 2008, 51 (4), 948. 
50. Cheng, C.; Sun, J.; Xing, L.; Xu, J.; Wang, X.; Hu, Y., J. Org. Chem. 2009, 74
(15), 5671. 
51. Farooq, T.; Haug, B.; Sydnes, L.; Törnroos, K., Monatsh. Chem. 2012, 143 (3), 
505. 
52. Yap, A. H.; Weinreb, S. M., Tetrahedron Lett. 2006, 47 (18), 3035. 
56
53. Dabbagh, H. A.; Rasti, E.; Najafi Chermahini, A., J. Mol. Struct.: 
THEOCHEM 2010, 947 (1-3), 92. 
54. OzimiĔski, W. P.; Dobrowolski, J. C.; Mazurek, A. P., J. Mol. Struct. 2003,
651-653 (0), 697. 
55. Abboud, J.-Luis M.; Foces-Foces, C.; Notario, R.; Trifonov, Rostislav E.; 
Volovodenko, Anna P.; Ostrovskii, Vladimir A.; Alkorta, I.; Elguero, J., Eur. J. Org. 
Chem. 2001, 2001 (16), 3013. 
56. CCDC 860712 contains the supplementary crystallographic data for 18c. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif:  
57. Parkanyi, L.; Kalman, A.; Argay, G.; Schawartz, J., Acta Crystallogr., Sect. B 
1977, B33, 3102. 
58. CCDC 860711 contains the supplementary crystallographic data for 25. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif:
59. Kalisiak, J.; Sharpless, K. B.; Fokin, V. V., Org. Lett. 2008, 10 (15), 3171-
3174. 
57
  
Chapter 3 
Synthesis of piperidine-based building 
blocks 
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3.1 Introduction 
Proteases were once considered to function primarily as “enzymes of digestion”, but 
are now recognized as the largest and most diverse class of enzymes.1 Four main 
classes of proteases include aspartic, serine, cysteine and metallo, are critical for their 
control over protein synthesis, and function enable them to regulate physiological 
processes such as digestion, growth, differentiation, wound healing and apoptosis.2
Proteases are also critical for disease propagation, and inhibitors of such proteases are 
emerging with promising therapeutic uses.2 In recent years, the scientific interest in 
protease inhibitors has been enormous both in private industry and in academia. 
Numerous protease inhibitors are currently in development in the pharmaceutical 
industry. A number of these belong to the group of aspartic proteases which are 
involved in key processes that are related to several human disease.3,4,5 Currently, 
different aspartic proteases are being targeted for the development of new medicines 
for use in the treatments of a range of conditions including malaria (plasmepsins), 
hypertension (renin), Alzheimer’s disease (ȕ-secretase) and HIV/AIDS (HIV-1-
protease).6,7  
The function of aspartic proteases depends on the presence of two aspartic acid 
residues in the active site (Figure 3.1). A water molecule is bound between the two 
catalytic Asp residues, and through a “push-pull” general acid-base mechanism the 
water molecule acts as a nucleophile that attacks the carbonyl of the peptide bond to 
be broken (scissile peptide bond).8,9 
Most aspartic proteases recognize and bind a 6-10 amino-acid stretch of their 
substrates,8 but the enzymatic cleavage of the substrate depends on several key events 
to occur. The enzyme active site is covered by a flap region (Figure 3.3 A), and to 
allow for substrate entry into the active site, this flap must first be opened, and then 
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closed again over the substrate in the catalytic cleft during enzyme catalysis.9 To 
allow for diffusion of products from the active site the flap region needs to re-open 
after the substrate hydrolysis has occurred. 
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Figure 3.1 General acid-base catalytic mechanism for aspartic proteases (porcine 
pepsin numbering) 
Due to peptidic nature, early protease inhibitors were often found to have poor oral 
absorption, low bioavailability and metabolic instability, and further development of 
these compounds into non-peptide peptidomimetic drugs has been necessary.10 In the 
search for tight binding inhibitors, structure-based drug design has proved to be an 
effective tool. Access to protease-inhibitor crystal structures, has opened the way for 
reduction of the molecular weight of inhibitors as well as reducing the peptidic 
features, and allowed for designed selectivities in lead inhibitors.2
The aspartic protease renin is secreted by special kidney cells via three responses, a 
decrease in arterial blood pressure, decrease in the NaCl level in ultra-filtrate of the 
nephron and following sympathetic nervous system activity. It plays an important role 
in controlling the blood pressure. An overactive renin-angiotensin system leads to 
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vasoconstriction and retention of sodium and water, causing hypertention. Renin 
inhibitors can be used for the treatment of hypertension.11, 12 Several renin inhibitors 
with low molecular weight, less peptidic character and improved bioavailability have 
been reported.13         
In recent years, piperidines have proven to be efficient scaffolds for the development 
of novel non-peptide aspartic protease inhibitors.6,7,10 In this project we planed to 
elaborate on these findings, and develop novel inhibitors with a central piperidine 
moiety.   
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Figure 3.2 Piperidine aspartyl protease inhibitors6,14,13 
An X-ray crystal structure of a piperidine inhibitor bound to renin, revealed a 
different binding mode of inhibitor compared to peptide based inhibitors (Figure 3.3 
B).14 This new concept of a central piperidine as a scaffold in the development of 
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aspartic protease inhibitors has lead to several tight binding compounds used in 
clinical testing.15   
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Figure 3.3 A) Schematic diagram of the active site conformation of Plasmepsin II 
(left) when bound to a “diamine-clamp” inhibitor16 and B) Binding mode of 
piperidine inhibitor to renin. 
The protonated nitrogen of the piperidine is bound between the two catalytically 
active aspartic acid residues (Asp32 and Asp215 in the case of renin, see Figure 3.3 
B), thereby displacing the water molecule necessary for peptide bond cleavage 
(Figure 3.1). Further, the 4-substituent displaces a tyrosine residue which is 
positioned on the flap that normally closes the active site (Tyr75 in the case of renin). 
The 3-substituent binds in a hydrophobic S1/S3 super pocket. A similar binding of 
“diamine-clamp” inhibitors and acylguanidine inhibitors to plasmempsins (Figure 3.3 
A) and ȕ-secretase, respectively has recently been reported.16,17 
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Purpose of the project 
Based on the aforementioned facts, 3-alkoxypiperidines with a 1,2,3-triazole-
containing substituent in position 4 (Figure 3.4) seem to constitute a promising group 
of novel non-peptide aspartic protease inhibitors. The purpose of this project has been 
to find out how promising these derivatives are in this respect.  
Figure 3.4 Target molecules  
In this context, in the course of our efforts to prepare 1,2,3-triazloes and in the 
development of 3,4-disubstituted piperidine as building blocks,18 we envisage that 
piperidine A could be a useful building block for the synthesis of a series of novel 
piperidines. 
Scheme 3.1 Synthetic plan for piperidine based building block
64
Different polar groups could be introduced at R1 position under Cu(I) and Ru(II)-
catalyzed 1,3-dipolar cycloadditions to enhance the inhibiting properties of these 
piperidine-based inhibitors. In order to modulate the binding ability, we envisioned 
that different groups could be introduced at as the R2 substituent through O-
alkylation. This would require that a synthetic route to building block A is 
established, and the use of the building block towards the synthesis of representative 
inhibitors B and C.          
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3.2 Synthesis of piperidine-based building block 
3.2.1 Synthesis of starting material  
Scheme 3.2 Retrosynthesis for A  
We envisioned that building block A could be prepared from the corresponding 
alcohol D, which should be assesible from keto ester E (Scheme 3.2).     
In order to obtain starting material, we followed the synthetic route described by 
Knight et al.19 which relies on Dieckmann cyclization to establish the piperidine ring. 
The N-alkylation of pyrrolidin-2-one (30) by ethyl bromoacetate provided ethyl 2-(2-
oxopyrrolidin-1-yl)acetate (31), which was hydrolysed to give 4-
(carboxymethylamino)butanoic acid hydrochloride (32) in high yield. The subsequent 
esterification led to methyl 4-(2-methoxy-2-oxoethylamino)butanoate hydrochloride 
(33) (Scheme 3.3). 
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Scheme 3.3 Synthesis of starting material 
In the following step, protection of the piperidine N-atom with a Boc protecting group 
gave methyl 4-(tert-butoxycarbonyl(2-methoxy-2-oxoethyl)amino)butanoate (34). 
Finally, Dieckmann cyclization led to 1-tert-butyl 4-methyl 3-oxopiperidine-1,4-
dicarboxylate (35) in 28% yield and 1-tert-butyl 2-methyl 3-oxopiperidine-1,2-
dicarboxylate (36) in 36% yield (Scheme 3.3). Attempts to receive required starting 
material 35 in higher yield failed. 
According to Zhang et al.20, commercially available ethyl 1-benzyl-3-oxopiperidine-
4-carboxylate hydrochloride (37) could be debenzylated in 4 hr. However, this Pd-C 
catalyzed hydrogenation reaction requires an elevated hydrogen pressure (4.9 atm) to 
go to completion. We managed to produce ethyl 3-oxopiperidine-4-carboxylate 
hydrochloride (38) in 2 hr by Pd-C catalyzed N-debenzylation of 37, by following a 
novel procedure reported by Cheng et al.21 in 2009 (Scheme 3.4). The trichloroalkane 
undergoes a chemoselective monodehydrochlorination to release HCl which 
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accelerates the normal hydrogenolysis process even at room temperature and 
atmospheric pressure.21        
Scheme 3.4 Removal of benzyl group  
In the next step, the protection of amine in 38 was accomplished to generate 1-tert-
butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (39) in 85% yield (Scheme 3.5).22  
Scheme 3.5 Protection of amine functionality 
Scheme 3.6 Reduction of ketone 
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Subsequently, the keto ester 39 was reduced with 1.1 equivalents of NaBH4 in 
methanol to give an inseparable mixture of diastereomeric hydroxyl ester 40 in 
excellent yield (96%) in 1 hr (Scheme 3.6). All attempts to achieve a satisfying 
separation of the two diastereomers using silica gel chromatography failed. From the 
complex proton spectrum, it was not possible to elucidate the cis/trans ratio of 40, 
however, Hanessian et al.23 has earlier repoted a 4:1 ratio of cis/trans in 96% yield 
after 3 hr when 0.6 equivalents of NaBH4 was utilized in EtOH as solvent at room 
temperature for the reduction of 39.  
Scheme 3.7 TBDMS protection of hydroxyl functionality 
The cis/trans mixture of 40 was subjected to TBDMS protection of the secondary 
alcohol, and the products, trans-1-tert-butyl 4-ethyl 3-(tert-
butyldimethylsilyloxy)piperidine-1,4-dicarboxylate (trans-41) and cis-1-tert-butyl 4-
ethyl 3-(tert-butyldimethylsilyloxy)piperidine-1,4-dicarboxylate (cis-41) were easily 
separated by flash column chromatography (Scheme 3.7). In early experiments, trans
41 and cis 41 were obtained in variable ratios from 1:1.8 to 1:4.9 with combined 
yields of 79-82%. 
During exploratory experiments (reduction of 39 and subsequent TBDMS protection), 
interestingly, two new non polar fractions were detected in addition to trans-41 and 
cis-41 as indicated by thin layer chromatography. It turned out that the ester group of 
39 also to some extent has been reduced, and the two new products that were formed 
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were found to be trans/cis-tert-butyl 3-(tert-butyldimethylsilyloxy)-4-((tert-
butyldimethylsilyloxy)methyl)piperidine-1-carboxylate (trans-42 and cis-42). The 
structural and stereochemical features of trans-42 and cis-42 were elucidated by 
spectroscopic analyses and finally also unequivocally substantiated by a high yield 
independent syntheses at later stages (see Scheme 3.19 and 3.20). Due to the 
formation of the protected diols, the ratio between trans-41 and cis-41 was also found 
to be disturbed and inconsistent (Scheme 3.8 and Table 3.1).     
Scheme 3.8 Reduction of ketone 39 and subsequent TBDMS protection 
  
Indeed, the production of diols during the reduction of 39 by NaBH4 in methanol was 
not surprising. Gohimukkula et al.24 have also found that an inseparable mixture of 
cis and trans diols in a 2:1 ratio were formed as the only products when 39 was 
reduced by using NaBH4 in a mixture of THF and methanol as a solvent. 
Unfortunately, incomplete experimental details were reported (Scheme 3.9).   
Scheme 3.9 Synthesis of cis and trans diols24
70
Scheme 3.10 Synthesis of diols (cis and trans)25,26
Similarly, an earlier account by Lewis et al.25, described the reduction of N-benzyl 3-
oxo-4-carboxylate using 20 mol equivalents of NaBH4 in MeOH at room temperature 
in 24 hr to give trans-c (22%) cis-d (77%) diols, which were separable using silica gel 
chromatography (Scheme 3.10). Sørensen et al.26, reported to obtain a mixture of c 
and d in a ratio of 1:3.7 in a combined yield of 80% after employing 12 equivalents of 
NaBH4 in the reduction. Separation of the cis and trans isomers was achieved using 
preparative HPLC. Gijsen et al.27 have argued that due to the enolic nature of the 3,4-
piperidine bond in ȕ-keto esters like 39, invariably a mixture of cis and trans
diastereomers is produced with cis isomer as the expected major product. Keeping in 
mind the aforementioned literature reports, we could expect the formation of diols 
during the reduction of 39. However, we have used only 1.1 mol equivalents of metal 
hydride and we have observed interesting variations in product ratios separated after 
the TBDMS protection step (Table 3.1).  
In initial experiments, the formation of cis ester 41 dominated over the corresponding 
trans ester 41 in the reduction step (Table 3.1, entery 1 and 2). In both                        
cases, the reactions were found to give as the major product the piperidine derivative 
with a cis relation between the ester group at C-4 and the hydroxyl group at C-3. We 
considered that the reduction took preferentially place by route a, i.e. from the 
opposite side of the Boc group (Scheme 3.11). The reason for this selectivity could be  
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Scheme 3.11 A possible mechanism for the predominance of cis product 
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explained by steric restrictions imposed on the system by the bulky Boc group which 
hinderes the hydride attack by route b. The dominance of cis ester 41 increased at the 
expense of trans-41 when reaction was performed at a higher concentration (Table 
3.1, entry 3). This suggests that in solution with high concentration, the 
intermolecular interaction become more pronounce, increase the steric restriction for 
attacking hydride which then predominantly attack from path a. A possible 
mechanism for the attack of sodium borohydride for the reduction of keto moity in 39
is depicted in Scheme 3.11.28,29 
Table 3.1 Summery of reduction of 39 and subsequent TBDMS protection 
Yield (%) step 2b Scale step 1a
(mmoles, conc.) 
mole eq. 
NaBH4
Time 
step 1 
Temp. 
step 1
Yield (%) 
40 t-41 c-41 t-42 c-42 
1 5.54 0.185 M 1.10 40 min -12 ºC 79 28 51 n.d n.d 
2 28.5 0.204 M 1.02 1 hr -12 ºC 96 14 68 n.d n.d 
3 18.42 0.263 M 1.10 2 hr -12 to -10 ºC 99 (crude) 5 70 n.d n.d 
4 26.1 0.522 M 1.10 2 hr -15 to -12 ºC 74 8 72 18 trace 
5 18.11 0.453 M 1.10 4 hr -15 to -10 ºC 61 2 48 48 trace 
6 1.69 0.338 M 1.10 24 hr -12 ºC 1
st hr 
then r.t. 91 (crude) 18 61 15 trace 
7 0.76 0.475 M 2.00 4 hr -12 to -10 ºC 96 7 61 27 trace 
a) Keto-ester 39 in Methanol.  b) TBDMS protection step  
The reduction of ketones by metal hydrides which can yield diastereomeric alcohols, 
has been studied extensively on acyclic, cyclic and polycyclic compounds. 30,31,32   
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Dauben et al.33 has evaluated two interpretations of the stereochemical results of the 
hydride reduction; product development control and steric approach control. The 
former effect would favour the more stable product whereas the latter would favour 
the least hindered approach. Our results suggest that the reaction is more governed by 
steric approach factors leading to cis product and not to thermodynamically more 
stable trans product with equatorial hydroxyl group.   
While in further experiment with double concentration, the generation of double 
protected trans diol 42 and a fraction of cis diol 42 along with the dominant product 
cis ester 41 seems to be controlled by intramolecular hydrogen bonding between the 
ester group and hydroxyl moiety (or OBH3-) that determines the route of hydride 
attack on ester group leading to trans diol. According to Våbeno et al.34 chelation 
control could be important to explain the stereochemical outcome of reduction 
reactions in favour of trans-diastereomer. Chelation control involves the coordination 
of chelating atom (M), often boron or other ions in reducing agent. Generally, 
monovalent counter ions such as Na+ or Li+ are not expected to produce stable 
chelates. However, NaBH4 in EtOH has been reported to show a slight chelation 
effect.34  So, we could expect in our case, O,O-chelation between carbonyl oxygen, 
oxygen of hydroxyl group and the metal ion, resulting in a six membered ring 
structure which could have blocked one face of the carbonyl and directed the hydride 
attack from the opposite side leading stereoselectively to the trans diol (Scheme 
3.12). This could be the reason that almost only trans diol 42 was formed with only 
traces of cis diol 42 (Table 3.1).  
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Scheme 3.12 A possibile chelation of Na+ 
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From the Table 3.1 it is evident that the trans diol is produced faster than the cis diol. 
Also, epimerization occurred during the formation of trans diol 42 from cis hydroxy 
ester 41 since trans 42 and cis 41 were isolated in a 1:1 ratio after TBDMS protection 
(Table 3.1, entry 5). However, with the generation of trans diol 42, the cis/trans ratios 
of cis products (cis 41 and cis 42) and trans products (trans 41 and trans 42) were 
found to nearly 2:1 (Entry 6 and 7) which were 4.9:1 and  14:1 (Entry 2 and 3), a clear 
indication of epimerization of the Į-carbon atom,  i.e. C-4 of the piperidine. We 
suggest that chelation effect or epimerization or both factors are responsible for the 
formation of almost only trans diol 42 from the cis ester 41.              
Our interests in trans ester 41, obtained in lower yield, prompted us to explore the 
possibility to convert the cis 41 into the trans 41. In the first exploratory experiment, 
the cis isomer was treated with 2 equivalents of anhydrous K2CO3 in ethanol at room 
temperature. The reaction progress was monitored by thin layer chromatography up to 
48 hr however, only the starting material was recovered in quantitative yield. For 
epimerization,35 a recent report by Molinaro et al. 36 successfully describes the 
epimerization of the Į-carbon atom,  i.e. C-4 of the piperidine. For this purpose, 
NaOEt was used and depending on the source of NaOEt different cis/trans ratios were 
reported (Scheme 3.13). 
75
Scheme 3.13 Epimerization/saponification described by Molinaro et al.36
Following this procedure, the epimerization was repeated using 5 equivalents of 
commercially available 21 wt% NaOEt/EtOH in EtOH at 70 ºC for 1 hr. The trans/cis 
ratio was found to be 2.9:1; but the combined yield of the isomers was only 54%. 
However, no much change was observed when reaction was allowed to run even for 4 
hr (Scheme 3.14). Whereas, the cis to trans conversion was expected to be high as 
described by the report, 14:1 in favor of trans isomer (Scheme 3.13). 
Scheme 3.14 conversion of cis to trans  
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Scheme 3.15 Direct epimerization/saponification 
In a second approach, a direct epimerization/saponification using 5 equivalents of 2 
M NaOH in ethanol at 70 ºC was also performed. This gave an inseparable mixture of 
cis/trans-1-(tert-butoxycarbonyl)-3-(tert-butyldimethylsilyloxy)piperidine-4-
carboxylic acid (43) in addition to a mixture of cis/trans-1-(tert-butoxycarbonyl)-3-
hydroxypiperidine-4-carboxylic acid (44) with loss of the TBDMS group, were 
separated by flash column chromatography. However, again the combined yield 
obtained in this reaction was not more than 66% (Scheme 3.15). The TBDMS group 
was presumably lost during acidic work up. 
As a third approach, a sequential epimerization with a solution of 21wt% 
NaOEt/EtOH followed by saponification with 5 equivalents of 2 M NaOH, was also 
employed (Scheme 3.16). It has been demonstrated that under these conditions, the 
trans ester converts to trans carboxylic acid faster than the cis isomer, and in parallel, 
the cis ester would still equilibrate to the thermodynamically stable trans isomer, 
finally providing a better trans/cis ratio of carboxylic acids up to 99:1.36  
Scheme 3.16 Epimerization and saponification  
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Table 3.2 Epimerization and saponification at different pH 
Yield (%) 
Entry pH 
43 44 45 
1 2-3 18 29 5 
2 5 74 21 0 
It was found that at lower pH (2-3 in work up) the yield of 43 decreased notably and 
generation of 44 increased due to the cleavage of the acid sensitive TBDMS group 
and additionally a new fraction 1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridine-4-
carboxylic acid (45) was recovered in 5% as maximum (Table 3.2). Formation of 45
has also been reported to occur by Hanessian et al. 23 in a similar reaction.     
In order to avoid the cleavage of the TBDMS group and the formation of 44 and 45, 
the pH was adjusted to 5 during work up by using 0.5 M HCl solution (Table 3.2, 
entry 2). We were able to isolate 43 in relatively high yield (74%), however still with 
a significant cleavage of the TBDMS group as 21% of 45 was also isolated (Table 
3.2).  
Proceeding further, the reduction of the ester group in trans ester 41 to its 
corresponding alcohol (a crystalline solid), trans- tert-butyl 3-(tert-
butyldimethylsilyloxy)-4-(hydroxymethyl)piperidine-1-carboxylate (trans-46) was 
accomplished using lithium aluminium hydride in THF (Scheme 3.17, Figure 3.5).   
Scheme 3.17 Reduction of trans ester 41 
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Figure 3.5 X-ray structure of trans alcohol 46 
Likewise, a number of attempts were made to reduce the carboxylic acid group of 43 
into the alcohol. In fact, the required alcohol was not produced under below 
mentioned reaction conditions (Table 3.3). 
Table 3.3 Failed attempts to generate alcohol from 43 
Entry Reaction conditions Isolated yield 
1 LiAlH4, dry THF, -35 ºC, 2 hr - 
2 LiAlH4, dry THF, 0 ºC to reflux, 3 hr - 
3 DIBAL, dry THF, reflux, 5 hr - 
4 NaBH4/BF3.Et2O, dry THF, reflux, 24 hr37 7% 
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Following the procedure reported by Kato et al.38 borane-methyl sulfide complex 
(BMS) was employed in THF at 0 ºC to reduce the carboxylic acid group of 43, again 
a fraction of trans alcohol 46 was isolated and the rest was solely the starting material 
as confirmed by thin layer chromatography and spectroscopic analyses. However, 
when the reaction mixture was refluxed for 4 hr, the trans alcohol 46 as crystalline 
solid and cis alcohol 46 as clear oil were easily isolated by silica gel chromatography 
(Scheme 3.18). In fact, the cis/trans ratio of alcohols found to be dependent on the 
origin of carboxylic acid 43 (Table 3.4, entry 1 and 2).           
Scheme 3.18 Reduction of carboxylic acid 43 with BMS 
Table 3.4 (%) Yield of cis and trans alcohol 
Entry Source of carboxylic acid 43 (%Yield) t-46 (%Yield) c-46
1 1) 21 wt% NaOEt/EtOH, EtOH, 70 ºC, 
2) 2 M NaOH, 70 ºC 62 32 
2 2 M NaOH, 70 ºC 16 74 
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Indeed, as expected, the first approach (Table 3.4, entry 1) proved that carboxylic acid 
43 contained more trans isomer than the cis isomer but not that much as suggested by 
literature (trans/cis ratio of carboxylic acid is reported as 99:1 determined by HPLC 
assay).36 However, in our case, we received an inseparable mixture of cis and trans
carboxylic acid 43 (Scheme 3.16) which after reduction with BMS produced trans
and cis alcohol in 1.9:1 ratio which may correspond to trans/cis ratio in carboxylic 
acid 43. While in second approach (Table 3.4, entry 2) the predominance of cis
alcohol 46 (cis to trans ratio 4.6:1) suggested that during the formation of carboxylic 
acid 43 (Scheme 3.15), the cis ester 41 epimerizes only to a small extent and 
converted directly into cis carboxylic acid which subsequently produced cis alcohol as 
dominant isomer when reduced with BMS. So, by using the 21 wt% NaOEt/EtOH and 
2 M NaOH approach and subsequent reduction with BMS, we were able to generate 
trans alcohol 46 in comparatively better yield for further explorations.  
For confirmatory purposes, the primary hydroxyl group of cis 46 was protected using 
TBDMSCl and imidazole in DMF. The independently synthesized sample of double 
protected diol found to be same as cis 42 (Scheme 3.8) as substantiated by 
spectroscopic analyses (Scheme 3.19).  
Scheme 3.19 Synthesis of doubly protected diol cis 42
Secondly, selective cleavage of a primary TBDMS group in protected diol trans 42
was achieved by applying an earlier reported procedure.39 The resulting mono-
TBDMS compound was isolated as a crystalline solid in 72% yield and found to be 
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the trans alcohol 46 and the rest was starting material (Scheme 3.20). Thus, the trans
diol 42 found out to be exclusively the trans isomer (Actually, this experiment 
confirmed the stereochemistry of trans 42). 
Scheme 3.20 Selective deprotection of primary TBDMS group 
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3.2.2 Synthesis of tosylates  
In order to proceed further, both alcohol trans 46 and cis 46 were converted to their 
corresponding tosylates,40, 41 namely trans/cis-tert-butyl 3-(tert-
butyldimethylsilyloxy)-4-(tosyloxymethyl)piperidine-1-carboxylate (trans-47 and cis-
47) using p-toluenesulfonyl chloride in pyridine. The tosylate formation found to be a 
slow process, in both cases, the maximum isolated yield of trans-tosylate was 68% 
and cis-tosylate 53% after 48 hr and the unreacted starting material trans 46 and cis
46 were recovered in each case (Scheme 3.21 and 3.22). 
Scheme 3.21 Synthesis of tosylate from alcohol trans 46 
Scheme 3.22 Synthesis of tosylate from alcohol cis 46 
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The slow tosylate formation is might be due to the steric hindrance caused by the 
presence of a bulky TBDMS group close to the primary hydroxyl group in trans 46
and cis 46. This idea is further strengthened by a tosylation reaction reported by 
Gijsen et al.27 where they have managed to convert a primary hydroxyl group in diol 
into tosylate in excellent yield (98%) in 1 hr (Scheme 3.23).  
In our case, we wanted to keep secondary hydroxyl group protected with TBDMS 
group, due to future use of the Grignard-type reaction use to synthesize 1,5-
disubstituted 1,2,3-triazoles. In retrospect, the tosyation would selectively have 
worked better without the TBDMS group. However, separation of cis and trans
isomers was not possible without TBDMS-protection (Scheme 3.7 and 3.8).          
    
Scheme 3.23 Tosylate formation from diol27
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3.2.3 Synthesis of azides   
In the next step, both tosylates, trans 47 and cis 47 were converted to their 
corresponding azides,42 trans/cis-tert-butyl 4-(azidomethyl)-3-(tert-
butyldimethylsilyloxy)piperidine-1-carboxylate (trans-48 and cis-48) using NaN3 in 
DMF in excellent yield of 99% and 91% respectively.43 However, the conversion of 
trans tosylate to trans azide found to be almost two times faster than the conversion 
of cis tosylate to cis azide, as observed by thin layer chromatography analyses 
(Scheme 3.24).     
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Scheme 3.24 Synthesis of piperidine based azides as new building blocks  
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Organic azides are energy rich molecules, heat and shock sensitive and can 
decompose explosively with the slightest input of external energy. Caution should be 
exercised when designing target azides and using them. The following equation44
gives some general guidelines to consider when working with organic azides. 
(NC + NO) / NN   3 
The total number of nitrogen atoms in organic azide should not exceed that of carbon. 
Azides with a C/N ratio greater than one but no more than three can be synthesized 
and isolated, but by no means should these molecules be stored in their highest purity. 
Rather, they should be stored as solutions below room temperature. Under no 
circumstances should organic azide with C/N ratio less than one be isolated.45
Alternatively, the “rule of six:” six carbons (or other atoms of about the same size) 
per energetic functional group (nitro, diazo, azide etc.) should provide enough 
dilution to render the compound relatively safe to work with under appropriate safety 
procedures.44        
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3.3 Piperidine based organic azide and Cu-catalyzed 1,3- dipolar 
cycloadditions 
With the aim of forming piperidine based 1,4-disubstituted 1,2,3-triazoles selectively, 
the trans azide 48 was added to alkynes under Cu(I)-catalyzed 1,3-dipolar 
cycloadditions (Scheme 3.25). For this purpose, Cu(II) sulphate and sodium ascorbate 
were used to generate  in situ Cu(I) which could catalyze the cycloaddition reaction 
(Scheme 3.25 and Chapter 2).43,18
Scheme 3.25 Cu-catalyzed cycloadditions 
 Table 3.5 Isolated yields of 1,4-disubstituted 1,2,3-triazoles 
Entry R1 Conditions 1,2,3-triazole (%)Yield
1 Ph THF/H2O (1:1), r.t., 48 hr 49 64 
2 Ph Dioxane/H2O (3:1), 65 ºC, overnight 93 
3 CH3OCO Dioxane/H2O (3:1), 65 ºC, 12 hr 50 96 
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As mentioned earlier, organic azides are potentially unstable and difficult to handle 
due to potential explosion danger, thus their in situ generation is considered to be 
advantageous.45 However, in our case, we found both trans 48 and cis 48 to be stable 
azides and thus easy to handle, but still we were interested to generate azide in situ 
from trans tosyale 47 during copper-catalyzed 1,3-dipolar cycloaddition reactions 
(Scheme 3.26).     
Scheme 3.26 Cu-catalyzed cycloadditions using in situ azide 
Table 3.6 Isolated Yields of 49 prepared from in situ azide 
Entry Solvent Temp (ºC) Time (h) (%) Yield 49
1 DMF 65 30 53 
2 DMSO 65 30 26 
3 CHCl3/EtOH/H2O (9:1:1) r.t. 40 - 
In case of reaction in DMF or in DMSO, first the tosylate was stirred with sodium 
azide at 65 ºC for 5-6 hrs to form the azide then phenyl acetylene and the copper 
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catalyst were added and stirring continued for 24 hr (Table 3.6, entery 1and 2). In 
both cases, at the end of reaction, the unreacted azide trans 48 was recovered along 
with 49. However, when the reaction was performed in CHCl3/EtOH/H2O at room 
temperature, unreacted tosylate was recovered in quantitative yield.     
In order to synthesize 1,4-disubstituted 1,2,3-triazoles containing 3,4-disubstituted 
piperidines as central moiety, at first, the acid sensitive TBDMS group was removed. 
Both the 1,4-disubstituted 1,2,3-triazoles, 49 and 50 were treated with TBAF in dry 
THF, stirred overnight at room temperature to receive corresponding unprotected 
1,2,3-triazoles 51 and 52 respectively (Scheme 3.27).46,47  
Scheme 3.27 Removal of protecting group 
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Figure 3.6 Crystal Structure of 51 
Table 3.7 Endocyclic bond lengths (Å) and angles (º) for the triazole ring in 51
Atoms Bond length Atoms Angle 
N(1)-N(2) 1.337 N(2)-N(1)-C(5) 111.32 
N(1)-C(5) 1.324 N(3)-C(4)-C(5) 106.62 
 C(4)-N(3) 1.358 N(3)-C(4)-C(6) 124.12 
C(4)-C(5) 1.376 N(3)-N(2)-N(1) 106.46 
N(2)-N(3) 1.317 N(1)-C(5)-C(4) 105.84 
C(5)-H1 0.951 N(1)-C(5)-H1 127.07 
N(2)-N(3)-C(4) 109.75 
Crystal system: monoclinic, Density: 1.238 Mg/m3, Volume: 1922.8(5) Å3, Unit cell 
dimentions: a = 14.051(2), b = 11.1079(17), c = 13.266(2) Å, Į= 90°, ȕ= 111.779(2)°, 
Ȗ = 90° 
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Proceeding further, the introduction of side chain at hydroxyl group in 51 and 52 by 
O-alkylation was attempted using NaH, TBAI and 2-bromomethylnephthalene, 
following a reported procedure.48 The O-alkylation on 51 proceeded well to furnish 
53 in excellent yield (Scheme 3.28). 
Scheme 3.28 O-alkylation step 
However, when attempts were made for the O-alkyation on triazole 52 under same 
conditions, two new products were isolated after flash column chromatography 
(Scheme 3.29).  
Scheme 3.29 Attempted O-alkylation of 52 
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Basic hydrolysis of ester functionality generated carboxylate anion which attacked on 
bromide of 2-bromomethylnephthalene under nucleophilic substitution reaction to 
produce 54. While carboxylate anion under acidic work up produced 55 (Scheme 
3.29).49,50 
In order to avoid the formation of unwanted 54 and 55 we decided to apply an 
alternative route. For this purpose, the protecting group TBDMS in trans azide 48
was removed to generate trans-tert-butyl 4-(azidomethyl)-3-hydroxypiperidine-1-
carboxylate (56) (Scheme 3.30). 
Scheme 3.30 Removal of TBDMS 
In the subsequent step, the hydroxyl group in newly synthesized trans azide 56
underwent O-alkylation to produce trans-tert-butyl 4-(azidomethyl)-3-(naphthalene-2-
ylmethoxy)piperidine-1-carboxylate (57) in excellent yield (Scheme 3.31).    
Scheme 3.31 O-alkyation of trans-azide 56 
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Now with the formation of alkoxy substituted trans azide 57, we were in a position to 
use this for the synthesize of 1,4- or 1,5-disubstituted 1,2,3-triazoles under Cu-
catalyzed or Ru-catalyzed 1,3-dipolar cycloadditions.   
The copper-catalyzed 1,3-dipolar cycloaddition of trans azide 57 and methyl 
propiolate under previously mentioned conditions afforded 1,4-disubstituted 1,2,3-
triazole 58 (Scheme 3.32).      
Scheme 3.32 Cu-catalyzed cycloaddition of 57 and methyl propiolate
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3.4 Piperidine based organic azide and Ru-catalyzed 1,3- dipolar 
cycloadditions 
To further explore the reactivity of trans azide 48, a representative 1,5-disubstituted 
1,2,3-triazole, trans-tert-butyl 3-(tert-butyldimethylsilyloxy)-4-((5-phenyl-1H-1,2,3-
triazol-1-yl)methyl)piperidine-1-carboxylate (59) was synthesized by reacting trans
48 and phenyl acetylene under Ru-catalyzed 1,3-dipolar cycloaddition (Scheme 3.33 
and Chapter 2). 
Scheme 3.33 Ru-catalyzed 1,3-dipolar cycloaddition 
In the subsequent step, the protecting group, TBDMS of 59 was removed by 
previously mentioned procedure (Scheme 3.27 and 3.30) to give trans-tert-butyl 3-
hydroxy-4-((5-phenyl-1H-1,2,3-triazol-1-yl)methyl)piperidine-1-carboxylate (60) 
(Scheme 3.34). Further, 60 was subjected to O-alkylation reaction under 
aforementioned conditions (Scheme 3.28 and 3.31) to afford 61 in high yield (Scheme 
3.34). 
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Scheme 3.34 TBDMS removal and subsequent O-alkylation
Finally, in order to remove the Boc group, the 1,4-disubstituted 1,2,3-triazoles 53 and 
58, and 1,5-disubstituted 1,2,3-triazole 61 were stirred with TFA in dichloromethane 
for 30 min and subsequently purified by preparative HPLC before bio-assay.  
Scheme 3.35 Removal of Boc group 
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3.5 Renin assay 
The 1,4-disubstituted 1,2,3-triazoles 62 and 63 and 1,5-disubstituted 1,2,3-triazole 64 
were tested to inhibit the renin activity.  
The 1,5-disubstituted 1,2,3-triazole 64 was found comparatively more efficient to 
inhibit renin activity than its counterpart 1,4-disubstituted 1,2,3-triazole 62. Whereas, 
the 1,4-disubstituted 1,2,3-triazole 63 was found to be the least efficient to show 
inhibition activity compared to other two 1,2,3-triazoles (Table 3.8).  
Table 3.8 Inhibition activity % towards renin, 5 µM compound concentration
 Renin 
Compound 5 uMa 
62 18.1 
63 11.2 
64 23.6 
a 3 parallels, all parallels diverge no more than 11.5 % from the mean value in average 
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3.6 Summery 
A synthetic route has been developed for the preparation of cis and trans 3,4-
disubstituted piperidine as building blocks for the synthesis of a series of novel 
piperidines.  
During the synthesis of cis and trans 3,4-disubstituted piperidines, the epimerization 
leading to the generation of diol cis 42 and conversion of cis ester 41 into trans 41 has 
been studied although more experiments are required for complete understanding.   
Further, trans 3,4-disubstituted piperidine building block was employed for the 
synthesis of representative 1,4- and 1,5-disubstituted 1,2,3-triazoles under Cu(I)- and 
Ru(II)-catalyzed 1,3-dipolar cycloadditions. These triazoles when tested as renin 
inhibitors, showed considerable inhibition property.  
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Concluding remarks 
In the first part of the project, 1,4-disubstituted 1,2,3-triazoles have been generated by 
reacting benzyl azide with two densely functionalized terminal alkynes, 3,3,4,4-
tetraethoxybut-1-yne (TEB) and 1,1-diethoxy-but-3-yn-2-one (keto-TEB), in 
moderate to good yields in different solvent systems. However, we were unable to 
generate corresponding 1,5-disubstituted 1,2,3-triazoles when Cp*RuCl(PPh3)2 was 
used as catalyst. The result was same for the TEB, when 1,5-disubstituted 1,2,3-
triazole synthesis via the addition of bromomagnesium acetylide to azide was 
attempted. We suggest that some other Ru-catalysts should be evaluated for the 
synthesis of 1,5-disubstituted 1,2,3-triazoles from these functionalized alkynes.  
N-Unsubstituted 1,2,3-triazoles (1H-1,2,3-triazoles) were prepared by using in situ
HCl accelerated catalytic hydrogenolysis over 10% Pd-C to remove N-benzyl 
substituent. When debenzylation reaction was further explored, it was observed that 
only the 1-benzyl 1,2,3-triazloes with at least one alkoxy substituent at C-atom of 
triazole ring underwent deprotection. Further research should be directed to 
investigate the role of alkoxy group, firstly in the debenzylation of 1-benzyl 1,2,3-
triazoles and secondly in the stabilization of C4-monosubstituted 1,2,3-triazoles.    
As a second part of the project, we have been able to establish a synthetic route for cis 
and trans 3,4-disubstituted piperidine as building blocks for the synthesis of a series 
of novel piperidines. Proceeding further, trans 3,4-disubstituted piperidine building 
block was used for the synthesis of 1,4- and 1,5-disubstituted 1,2,3-triazoles. These 
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piperidines with a triazolyl-methyl substituents showed considerable inhibition 
activity when applied as renin inhibitors. 
Keeping this in mind, further evaluation should be carried out by introducing different 
substituents at C4 or C5 of the triazole ring to enhance the inhibition properties. 
Structure-based drug design could help for the selection of substituents at C4 or C5 
for the improvement of these inhibitors. Likewise, attempts should be directed to 
modulate the binding ability of these inhibitors by introducing different groups at C3 
of the piperidine ring through O-alkylation. This could lead to the synthesis of novel 
aspartic protease inhibitors.            
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Chapter 5 
Experimental 
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Experimental 
5.1 General  
All chemicals were purchased from Sigma-Aldrich and were used without any further 
purification. Dry solvents were prepared by using mBraun SPS-800 solvent 
purification system. All anhydrous reactions were performed under inert atmosphere 
either by argon or nitrogen gases. TLC analyses were carried out using Silica gel (60 
F254) on aluminium sheets with mixtures of appropriate solvents as the mobile phase 
and visualization was made possible by staining with 2% ninhydrin in EtOH or 
ethanolic acidic phosphomolymdic acid solutions as appropriate. Purification by flash 
column chromatography was performed using Merk 60 Kieselgel (230-400 mesh) as 
the stationary phase and mixtures of hexanes and ethyl acetate as the mobile phase.  
Melting points were determined by using Stuart Scientific SMP3 melting point 
apparatus and are uncorrected.   
Infra-red spectra were recorded on a Nicolet Impact 410 infrared spectrophotometer 
or Nicolet 380 FT-IR spectrophotometer and the intensities are given as weak (w), 
medium (m), strong (s) and broad (br). The NMR spectra were recorded on a Bruker 
Spectrospin DPX-400 MHz spectrometer; the chemical shifts are reported in ppm 
relative to Me4Si, the coupling constants (J) in Hz, and the multiplicity as singlet (s), 
doublet (d), triplet (t) and multiplet (m). 13C NMR signals marked with * were 
recognized from cross peaks in respective HSQC spectra. The mass spectra were 
obtained on a JEOL AccuTOF T100GC, operated in the DART mode and MS-ESI 
were obtained on Thermo electron LTQ Orbitrap. GC-MS analyses were performed 
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on Trace Ultra GC coupled with a DSQII quardpole MS detector from Thermo 
Scientific. Purification by reversed-phase high performance liquid chromatography 
(RP-HPLC) was performed using a C18-column (Ascentis® C18, 5 µm, 21.2x250 mm, 
Supelco Corp., Bellefonte, PA, USA) with a mixture of water and acetonitrile (both 
containing 0.1 % TFA) as mobile phase and UV detection at 220 nm. Analytical RP-
HPLC was performed using a C18-column (Ascentis® C18, 5 µm, 4.6x250 mm, 
Supelco Corp., Bellefonte, PA, USA). 
1,1-Dichloro-2-ethoxycyclopropane (1) 
The title compound was prepared in 84% yield according to already published 
procedure. The spectroscopic data were in agreement with literature values.1  
1H NMR (400 MHz, CDCl3): į 1.28 (t, J = 7.1, 3H), 1.51 (dd, J = 8.2, 5.1, 1H), 1.56 
(t, J = 8.5, 1H), 3.53 (dd, J = 8.2, 5.1, 1H), 3.65-3.90 (m, 2H).  
2-Chloro-3,3-diethoxyprop-1-ene  (2) 
The title compound was prepared in 57% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.1  
1H NMR (400 MHz, CDCl3): į 1.24 (t, J = 7.1, 6H), 3.46 – 3.72 (m, 4H), 3.65-3.90 
(m, 2H), 4.85 (t, J = 8.6, 1H), 5.46 (m, 1H), 5.68 (t, J = 1.2, 1H) 
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1,1-Dibromo-2-chloro-2-(diethoxymethyl) cyclopropane (3) 
&O
%U%U
2(W
(W2
The title compound was prepared in 56% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.2
1H NMR (400 MHz, CDCl3): į 1.15-1.30 (m, 6H), 1.93 (d, J = 9.4, 1H), 2.06 (d, J = 
9.4, 1H), 3.48 – 3.84 (m, 4H), 4.50 (s, 1H).  
3,3,4,4-Tetraethoxybut-1-yne (4) 
The title compound was prepared in 85% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.2,3 
1H NMR (400 MHz, CDCl3): į 1.17-1.30 (m, 12H), 2.60 (s, 1H), 3.63 – 3.84 (m, 8H), 
4.40 (s, 1H).  
1,1-Diethoxybut-3-yn-2-one (5) 
The title compound was prepared in 96% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.2
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1H NMR (400 MHz, CDCl3): į 1.26 (t, J = 7.1, 6H), 2.65 (s, 1H), 3.62 – 3.90 (m, 
8H), 4.67 (s, 1H).  
(Aazidomethyl)benzene (6)
The title compound was prepared in 96% yield according to already published 
procedure. The spectroscopic data were in agreement with literature. 4
1H NMR (CDCl3, 400 MHz): į 4.35 (s, 2H), 7.26-7.42 (m, 5H). 
5.2 Synthesis of 1,2,3-triazoles 
1-Benzyl-4-(1,1,2,2-tetraethoxyethyl)-1H-1,2,3-triazole (7) 
1
11
2(W
2(W2(W
(W2
3K
The ketal 4 (0.230 g, 1 mmol), benzyl azide (0.147 g, 1.1 mmol), CuSO4.5H2O (9.3 
mg, 0.04 mmol)/sodium ascorbate (22 mg, 0.11 mmol) were suspended in a 
water/DMSO (1:3) (4 ml).The mixture was stirred vigorously at 60 ºC for 48 hr. After 
extraction with EtOAc (10 ml x 3), combined organic layer was washed with brine, 
dried over anhydrous MgSO4 and concentrated. Purification of the crude product with 
flash column chromatography using (hexane-EtOAc, 7:3) gave 7 (0.220 g, 74%); 
colorless solid, mp 74-75.5 ˚C; Rf = 0.35; IR: 3154 (s), 2986 (s), 2940 (m), 2886 (m), 
2366 (m), 2334 (w), 1613 (w), 1499 (w), 1458 (m), 1371 (m), 1188 (s), 1125 (s), 
1084 (s), 979 (m), 928 (m), 842 (m), 728 (s), 687 (m) cm-1; 1H NMR (400 MHz, 
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MeOD): į 1.08 (t, J = 7.0 Hz, 6H), 1.66 (t, J = 7.0 Hz, 6H), 3.41-3.71 (m, 8H), 4.72 
(s, 1H), 5.57 (s, 2H), 7.29-7.36 (m, 5H), 7.82 (s, 1H);  13C NMR (101 MHz, MeOD): 
į 14.6, 14.7, 53.9, 57.9, 65.5, 99.9, 104.7, 125.5, 128.1, 128.6, 129.1, 136.0, 147.3; 
HRMS (DART): m/z [M+H]+ calcd. for C19H30N3O4: 364.2236 found 364.2233. 
1-Benzyl-5-iodo-4-(1,1,2,2-tetraethoxyethyl)-1H-1,2,3-triazole (8) 
1
11
2(W
2(W2(W
(W2
3K
,
Ketal 4 (0.230 g, 1 mmol), benzyl azide (0.146 g, 1.1 mmol), CuI (0.209 g, 1.1 
mmol), diisopropyl-ethylamine (DIPEA) (0.129 g, 1 mmol), and N-chlorosuccinimide 
(NCS) (0.160 g, 1.2 mmol) were dissolved in THF (5 ml), and the resulting mixture 
was stirred vigorously at r.t for 4 hr. After extraction with EtOAc (10 ml x 3), 
combined organics were washed with brine, dried over anhydrous MgSO4 and 
concentrated. Purification of the crude product with flash column chromatography 
using (hexane-EtOAc, 7:3) gave 8 (0.352 g, 72%). When the reaction was repeated 
using N-bromosuccinimide (NBS) (0.213 g, 1.2 mmol) instead of NCS the yield of 8
dropped (0.302 g, 62%). yellowish crystalline solid; mp 83-84 ˚C; Rf = 0.60; IR: 2979 
(s), 2931 (m), 2899 (w), 2358 (s), 2340 (m), 1653 (m), 1557 (m), 1440 (m), 1241 (m), 
1209 (m), 1173 (w), 1121 (s), 1077 (s), 973 (s), 929 (m), 724 (s) cm-1 ; 1H NMR (400 
MHz, MeOD): į 1.12 (t, J = 7.0 Hz, 6H), 1.24 (t, J = 7.0 Hz, 6H), 3.51-3.71 (m, 8H), 
4.73 (s, 1H), 5.68 (s, 2H), 7.19-7.32 (m, 5H); 13C NMR (101 MHz, MeOD): į 14.3, 
14.4, 53.6, 57.6, 65.2, 99.6, 104.4, 125.2, 127.8, 128.3, 128.7, 135.7, 147.0; HRMS 
(ESI): m/z [M+H]+ calcd for C19H29N3O4I: 490.1197 found 490.1195. 
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1-(1-Benzyl-1H-1,2,3-triazole-4-yl)-2,2-diethoxyethanone (9) 
1
11
2(W
(W2 2
3K
The ketone 5 (0.156 g, 1 mmol), benzyl azide (0.147 g, 1.1 mmol) and CuI (19 mg, 
0.1 mmol) were suspended in acetonitrile (3 ml).The mixture was stirred vigorously at 
60 ºC for 48 hr and 2 ml water was added. After extraction with CH2Cl2 (5 ml x 3), 
combined organics were washed with brine, dried over anhydrous MgSO4 and 
concentrated. Purification of the crude product with flash column chromatography 
using (hexane-EtOAc, 7:3) gave 9 (0.240 g, 70%) and 10 (25 mg, 3%) ; For 9;
yellowish oil; Rf = 0.27; IR: 3127 (m), 3027 (w), 2975 (s), 2923 (m), 2891 (m), 1701 
(s), 1529 (s), 1490 (m), 1457 (m), 1369 (m), 1321 (w), 1241 (s), 1113 (m), 1065 (m), 
917 (w), 828 (m), 716 (s), 700 (w) cm-1;  1H NMR (400 MHz, CDCl3): į 1.22 (t, J = 
7.0 Hz, 6H), 3.65-3.81 (m, 4H), 5.45 (s, 1H), 5.57 (s, 2H), 7.29-7.40 (m, 5H) 8.12 (s, 
1H); 13C NMR (101 MHz, CDCl3): į 15.7, 54.9, 64.0, 100.9, 128.3, 128.9, 129.7, 
129.8, 134.1, 145.1, 187.7; HRMS (DART): m/z [M+H]+ calcd. for C15H20N3O3: 
290.1504 found 290.1525. 
1-(1-Benzyl-1H-1,2,3-triazole-5-yl)-2,2-diethoxyethanone (10) 
For 10; greenish oil; Rf = 0.51 (Hex/EtOAc, 7:3); IR (film): 3047 (w), 2987 (s), 2943 
(w), 2891 (w), 1709 (s), 1505 (w), 1449 (m), 1333 (m), 1245 (w), 1125 (m), 1073 (s), 
921 (w), 724 (s), 700 (m) cm-1; 1H NMR (400 MHz, CDCl3): į 1.20 (t, J = 7.0 Hz, 
3H), 3.51-3.69 (m, 4H), 4.93 (s, 1H), 5.29 (s, 2H), 7.30-7.32 (m, 5H), 8.47 (s, 1H); 
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13C NMR (101 MHz, CDCl3): į 15.5, 54.4, 64.0, 103.0, 128.6, 128.8, 129.2, 130.4, 
135.4, 140.6, 186.0; HRMS (DART): m/z [M+H]+ calcd. for C15H20N3O3: 290.1504 
found 290.1501. 
1-(1-Benzyl-5-iodo-1H-1,2,3-triazole-4-yl)-2,2-diethoxyethanone (11) 
1
11
2
2(W
(W2
3K
,
The Iodoketal 8 (0.489 g, 1.0 mmol) was dissolved in a mixture of acetone (18 ml) 
and water (0.5 ml) and Dowex 50W (0.260 g) was subsequently added. The mixture 
was heated at reflux for 6 hr and was then filtered, dried (MgSO4) and concentrated. 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 7:3) gave 11 (0.353 g, 85%); brownish oil; Rf = 0.50; IR: 3600 (m), 2975 (m), 
2931 (w), 2891 (w), 1713 (s), 1497 (s), 1461 (w), 1445 (m), 1421(m), 1097 (w), 1065 
(s), 980 (m), 920 (m), 710 (m) cm-1;  1H NMR (400 MHz, CDCl3): į 1.28 (t, J = 8.0 
Hz, 6H), 3.80-3.84 (m, 4H), 5.66 (s, 2H), 5.90 (s, 1H), 7.31-7.38 (m, 5H); 13C NMR 
(101 MHz, CDCl3): į 15.8, 54.6, 63.8, 98.6, 128.6, 128.8, 129.2, 129.3, 129.5, 133.9, 
187.6; HRMS (ESI): m/z [M+H]+ calcd for C15H19N3O3I: 416.0465 found 416.0466. 
1-Benzyl-5-phenyl-1,2,3-triazole (12) 
1
113K
3K
The title compound was prepared in 86% yield using Ru-catalyst according to already 
published procedure. The spectroscopic data were in agreement with literature.5
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1H NMR (400 MHz, CDCl3): į 5.54 (s, 2H), 7.05-7.07 (m, 2H), 7.23-7.28 (m, 5H), 
7.38-7.45 (m, 3H), 7.73 (s, 1H). 
1,3,5-tris(2,2-diethoxyacetyl)benzene (13) 
The title compound was received in 60% yield. The spectroscopic data were in 
agreement with literature.6  
1H MNR (400 MHZ, CDCl3): į 3.96 (s, 12H), 8.83 (s, 3H). 
General procedure for Cu-catalyzed cycloadditions (compound 15a-20a) 
Terminal alkyne (1.0 mmol), benzyl azide (1.1 mmol) and CuSO4.5H2O (9.3 mg, 0.04 
mmol)/sodium ascorbate (22 mg, 0.11 mmol) were suspended in 4 ml of 
water/CH2Cl2 (1:3). The reaction mixture was stirred vigorously at r.t for 12-48 hr 
(Table 1). After extraction with dichloromethane (10 ml x 3), the combined organic 
layers were dried over MgSO4, the drying agent was removed by filtration and the 
filtrate was concentrated under vacuum. Purification of the crude product using flash 
column chromatography eluting with mixtures of hexanes and ethyl acetate provided 
1,4-disubstituted 1,2,3- triazoles. 
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Methyl 1-benzyl-1H-1,2,3-triazol-4-carboxylate (15a) 
The title compound was prepared from methyl propiolate (84 mg 1.0 mmol) and 
benzyl azide (0.146 g, 1.1 mmol) according to the general procedure. Crystalline 
solid; Yield: 0.215 g (99%). The spectroscopic data were in accordance with those 
reported in the literature.7
1H NMR (400 MHz, CDCl3) į 3.93 (s, 3H), 5.58 (s, 2H), 7.69 – 7.26 (m, 5H), 7.97 (s, 
1H). 
1-Benzyl-4-phenyl-1H-1,2,3-triazole (12a)
1
11
3K
3K
The title compound was prepared from phenyl acetylene (0.102 g 1.0 mmol) and 
benzyl azide (0.146 g, 1.1 mmol) according to the general procedure. Crystalline 
solid; Yield: 0.233 g (99%). Analytical data were in accordance with those reported in 
the literature.8
1H MNR (400 MHZ, CDCl3): į 5.58 (s, 2H), 7.30-7.42 (m, 8H), 7.67 (s, 1H), 7.81 (d, 
J = 8.7 Hz, 2H). 
1,4-Dibenzyl-1H-1,2,3-triazole (16a)  
1
1 1
3K
3K
The title compound was prepared from prop-2-ynylbenzene (0.116 g 1.0 mmol) and 
benzyl azide (0.146 g, 1.1 mmol) according to the general procedure. 
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Light yellow crystalline solid; Yield: 0.237 g (95%). Analytical data were in 
accordance with those reported in the literature.9
1H NMR (400 MHz, CDCl3) į 4.07 (s, 2H), 5.46 (s, 2H), 7.16 – 7.53 (m, 11H). 
1-Benzyl-4-(methoxymethyl)-1H-1,2,3-triazole (17a)  
The title compound was prepared from methyl propargyl ether (70 mg 1.0 mmol) and 
benzyl azide (0.146 mg, 1.1 mmol) according to the general procedure. 
Light yellow oil; Yield: 0.201 g (99%). Analytical data were in accordance with those 
reported in the literature.10
1H NMR (400 MHz, CDCl3): į 3.39 (s, 3H), 4.55 (s, 2H), 5.52 (s, 2H), 7.26-7.37 (m, 
5H), 7.46 (s, 1H). 
1-Benzyl-4-(phenoxymethyl)-1H-1,2,3-triazole (18a)  
The title compound was prepared from phenyl propargyl ether (0.145 g 1.0 mmol) and 
benzyl azide (0.146 g, 1.1 mmol) according to the general procedure. 
Colorless crystals; Yield: 0.251 g (95%). Analytical data were in accordance with 
those reported in the literature.11
1H NMR (400 MHz, CDCl3): į 5.19 (s, 2H), 5.54 (s, 2H), 6.95-6.98 (m, 3H), 7.28-
7.30 (m, 5H), 7.37-7.39 (m, 2H), 7.53 (s, 1H). 
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1-Benzyl-4-(diethoxymethyl)-1H-1,2,3-triazole (19a) 
The title compound was prepared from 3,3-diethoxy-1-propyne (0.128 g 1.0 mmol) 
and benzyl azide (0.146 g, 1.1 mmol) according to the general procedure. 
Crystalline solid; Yield: 0.255 g (98%). Analytical data were in accordance with those 
reported in the literature.11
1H NMR (400 MHz, CDCl3): į 1.22 (t, J = 7.2 Hz, 6H), 3.54-3.70 (m, 4H), 5.51 (s, 
2H), 5.59 (s, 1H), 7.26-7.36 (m, 5H), 7.49 (s, 1H).
1-(1-Benzyl-1H-1,2,3-triazol-4-yl)ethanol (20a)  
The title compound was prepared from 3-butyn-2-ol (70 mg 1.0 mmol) and benzyl 
azide (0.146 g, 1.1 mmol) according to the general procedure. 
Crystalline solid; Yield: 0.197 g (97%). Analytical data were in accordance with those 
reported in the literature.12
1H MNR (400 MHZ, CDCl3): į 1.50 (d, J = 6.4 Hz, 3H), 4.93-4.97 (q, J = 7.2 Hz, 
1H), 5.57 (s, 2H), 7.31-7.36 (m, 5H), 7.83 (s, 1H).
1-(Benzyloxymethyl)-4-phenyl-1H-1,2,3-triazole (27)  
The title compound was prepared from phenyl acetylene (0.102 g 1.0 mmol) and 
((azidomethoxy)methyl)benzene (0.179 g, 1.1 mmol) according to the general 
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procedure. Colorless crystals; Yield: 0.203 g (77%). Analytical data were in 
accordance with those reported in the literature.13
1H NMR (400 MHz, CDCl3): į 4.58 (s, 2H), 5.79 (s, 2H), 7.32-7.39 (m, 6H), 7.45 (t, 
J = 7.2, 2H), 7.86 (d, J = 7.6, 2H), 7.95 (s, 1H). 
4-Benzyl-1-(benzyloxymethyl)-1H-1,2,3-triazole (29) 
The title compound was prepared from prop-2-ynylbenzene (0.116 g 1.0 mmol) and 
((azidomethoxy)methyl)benzene (0.179 g, 1.1mmol) according to the general 
procedure. Purification of the crude product with flash column chromatography using 
(hexane-EtOAc, 8:2) afforded the title compound. Thick semisolid; Yield: 0.253 g 
(91%); Rf = 0.11 (hexanes-EtOAc, 8:2); IR: 3062 (w), 3028 (w), 2872 (w), 1602 (w), 
1548 (w), 1493 (m), 1454 (m), 1434 (w), 1379 (m), 1346 (w), 1302 (w), 1222 (m), 
1096 (s), 1048 (s), 1026 (s), 797 (w), 755 (s), 737 (m), 725 (s), 694 (s) cm-1; 1H NMR 
(400 MHz, MeOD): į 4.06 (s, 2H), 4.54 (s, 2H), 5.73 (s, 2H), 7.19-7.31 (m, 10H), 
7.79 (s, 1H); 13C NMR (101 MHz, MeOD): į = 32.5, 72.4, 79.2, 123.9, 127.5, 129.1, 
129.4, 129.6, 138.0, 140.3, 149.2;; HRMS (ESI): m/z [M+Na]+ calcd for 
C17H17N3ONa: 302.1264; found 302.1269. 
1-(1-Benzyl-1H-1,2,3-triazol-4-yl)-2,2-diethoxyethanol (22) 
To a solution of ketone 9 (0.396 g, 1.37 mmol) in THF/H2O (9:1, 10 ml) at 0 ˚C was 
added NaBH4 (26 mg, 0.69 mmol) in one portion. After 30 minutes the starting 
material had been consumed and 0.1 M HCl (3 ml) was added. The aqueous layer was 
extracted with CH2Cl2 (3 x15 ml) and the combined organic layers were dried over 
119
MgSO4. The drying agent was removed by filtration and the filtrate was concentrated. 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 1:1) provided the title compound. Colorless oil; Yield: 0.340 g (85%); Rf = 
0.14 (hexanes-EtOAc, 1:1); IR: 3388 (br), 2975 (m), 2882 (w), 1737 (s), 1497 (w), 
1455 (w), 1333 (w), 1221 (w), 1119 (s), 1050 (s), 804 (w), 713 (s) cm-1; 1H NMR 
(400 MHz, CDCl3): į 1.12 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.2 Hz, 3H), 2.88 (d, J = 
4.4 Hz, 1H ) 3.52-3.56 (m, 2H),  3.69-3.81 (m, 2H), 4.72 (d, J = 4.8, 1H), 4.86 (t, J = 
4.4, 1H), 5.52 (s, 2H), 7.25-7.27 (m, 2H), 7.35-7.37 (m, 3H), 7.48 (s, 1H); 13C NMR 
(101 MHz, CDCl3): į 15.4, 15.5, 54.4, 64.2, 64.3, 104.1, 128.3, 128.9, 129.3, 134.8, 
147.4; HRMS (ESI): m/z [M+H]+ calcd for C15H21N3O3: 292.1656 found 292.1658. 
General procedure for Ru-catalyzed cycloadditions (15b-21b) 
Alkyne (1-1.8 mmol), organic azide (0.99-1.1 mmol) and Cp*RuCl(PPh3)2 (1 mol %) 
were dissolved in 8-10 ml of anhydrous C6H6  (or anhydrous THF). The resulting 
mixture was heated to at 80 ºC (or 65 ºC for THF) and stirred vigorously for 3-4 h 
(Table 1). After cooling to room temperature, the solvent was removed under vacuum. 
Purification of the crude product using flash column chromatography with mixtures of 
hexanes and ethyl acetate provided 1,5-disubstituted 1,2,3- triazoles. 
Methyl 1-benzyl-1H-1,2,3-triazol-5-carboxylate (15b)  
The title compound was prepared from methyl propiolate (84 mg, 1 mmol) and benzyl 
azide (0.146 g, 1.1 mmol) according to the general procedure for Ru-catalyzed 
cycloadditions using C6H6 at 80 ºC. 
Clear oil; Yield: 7 mg (3%). Analytical data were in accordance with those reported in 
the literature.14
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Trimethyl benzene-1,3,5-tricarboxylate (15C) 
The title compound was isolated after reacting methyl propiolate with benzyl azide 
following the general protocol for Ru-catalyzed cycloadditions. 
Yield: 72 mg, (97%). Analytical data were in accordance with those reported in the 
literature.15
1H NMR (400 MHz, CDCl3) į 3.97 (s, 9H), 8.83 (s, 3H).  
1-Benzyl-5-(methoxymethyl)-1H-1,2,3-triazole (17b) 
The title compound was prepared from methyl propargyl ether (70 mg, 1 mmol) and 
benzyl azide (0.146 g, 1.1 mmol) according to the general procedure for Ru-catalyzed 
cycloadditions using C6H6 at 80 ºC; Red-brown oil; Yield: 0.154 g (76%); Rf = 0.22 
(hexanes-EtOAc, 7:3 ); IR: 3032 (w), 2930 (w), 2825 (w), 1605 (w), 1593 (w), 1497 
(m), 1455 (s), 1331 (m), 1220 (m), 1190 (m), 1103 (s), 1084 (s), 1029 (m), 980 (m), 
954 (m),  906 (m), 836 (m), 755 (m), 717 (s), 694 (s) cm-1; 1H NMR (400 MHz, 
CDCl3): į 3.27 (s, 3H), 4.34 (s, 2H), 5.62 (s, 2H), 7.22-7.35 (m, 5H), 7.65 (s, 1H). 
13C NMR (101 MHz, CDCl3): į 52.6, 58.3, 62.6, 127.8, 128.6, 129.1, 133.3, 134.8, 
134.9;  HRMS (ESI): m/z [M+H]+ calcd for C11H13N3O: 204.1131  found 204.1132. 
121
1-Benzyl-5-(phenoxymethyl)-1H-1,2,3-triazole (18b) 
                                                          
The title compound was prepared from phenyl propargyl ether (0.145 g, 1.1 mmol) 
and benzyl azide (0.133 g, 1 mmol) according to the general procedure for Ru-
catalyzed cycloadditions using C6H6 at 80 ºC; Crystalline solid; Yield: 0.257 g (97%); 
Rf = 0.24 (hexanes-EtOAc, 7:3); mp 121.0-122.4 ºC; IR: 3132 (w), 2921 (w), 2871 
(w), 1737 (w), 1712 (w), 1598 (m), 1584 (m), 1494 (s), 1486 (s), 1428 (m), 1382 (m), 
1330 (m), 1237 (s), 1218 (s), 1177 (m), 1119 (m), 1053 (s), 1029 (s), 1005 (s),  987 
(m), 855 (m), 753 (s), 690 (s) cm-1; 1H NMR (400 MHz, CDCl3): į 4.90 (s, 2H), 5.69 
(s, 2H), 6.83 (d, J = 7.6, 2H), 7.02 (t, J = 7.2, 1H), 7.17-7.19 (m, 2H), 7.27-7.31 (m, 
5H) 7.73 (s, 1H); 13C NMR (101 MHz, CDCl3): į 52.8, 58.5, 114.8, 122.2, 127.8, 
128.7, 129.1, 129.9, 132.4, 134.6, 134.8, 157.7; HRMS (ESI): m/z [M+H]+ calcd for 
C16H16N3O: 266.1288 found 266.1290.      
                                                          
1-Benzyl-5-(diethoxymethyl)-1H-1,2,3-triazole (19b)                                   
The title compound was prepared from 3,3-diethoxy-1-propyne (0.230 g, 1.8 mmol) 
and benzyl azide (0.132 g, 0.99 mmol) according to the general procedure for Ru-
catalyzed cycloadditions using C6H6 at 80 ºC; Red brown oil; Yield: 0.206 g (79%); Rf
= 0.50 (hexanes-EtOAc, 7:3); IR: 2975 (m), 2930 (w), 2883 (w), 1606 (w), 1552 (w), 
1497 (w), 1455 (m), 1370 (w), 1231 (w), 1185 (w), 1109 (s), 1048 (s), 983 (m), 915 
(m), 842 (m), 720 (s) 694 (s), 577 (w) cm-1; 1H NMR (400 MHz, CDCl3): į  1.14 (t, J 
= 7.2 Hz, 6H), 3.41-3.50 (m, 4H), 5.41 (s, 1H), 5.62 (s, 2H), 7.21-7.30 (m, 5H), 7.69 
(s, 1H); 13C NMR (101 MHz, CDCl3): į 15.0, 52.6, 61.5, 94.6, 127.7, 128.4, 128.9, 
134.2, 135.0, 135.1; HRMS (ESI): m/z [M+H]+ calcd for C14H20N3O2: 262.1550 
found 262.1552. 
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1-(1-Benzyl-1H-1,2,3-triazol-5-yl)ethanol (20c) 
The title compound was prepared from 3-butyn-2-ol (70 mg, 1 mmol) and benzyl 
azide (0.133 g, 1 mmol) according to the general procedure for Ru-catalyzed 
cycloadditions using C6H6 at 80 ºC; Yellowish oil; Yield: 0.143 g (70%); Rf = 0.22 
(hexanes-EtOAc, 1:1); IR: 3263 (br), 2976 (m), 2931 (w), 1496 (m), 1455 (s), 1373 
(w), 1294 (w), 1233 (m), 1181 (w), 1113 (s), 1076 (s), 1027 (s), 984 (m), 889 (m), 833 
(m), 715 (s), 693 (s) cm-1; 1H NMR (400 MHz, CDCl3): į 1.14 (t, J = 7.2 Hz, 6H), 
3.41-3.50 (m, 4H), 5.41 (s, 1H), 5.62 (s, 2H), 7.21-7.30 (m, 5H), 7.69 (s, 1H); 13C 
NMR (101 MHz, CDCl3): į 22.5, 52.4, 60.3, 127.6, 128.5, 129.1, 131.7, 135.2, 140.2; 
HRMS (ESI): m/z [M+H]+ calcd for C11H14N3O: 204.1131 found 204.1133. 
1-Benzyl-4,5-bis(methoxymethyl)-1H-1,2,3-triazole (26) 
The title compound was prepared from 1,4-dimethoxybut-2-yne (0.114 g, 1 mmol) 
and benzyl azide (0.160 g, 1.2 mmol) according to the general procedure for Ru-
catalyzed cycloadditions using C6H6 at 80 ºC; Red brown oil; Yield: 0.202 g (82%); Rf
= 0.26 (hexanes-EtOAc, 1:1); IR: 2927 (w), 2820 (w), 1589 (w), 1497 (m), 1455 (m), 
1436 (m), 1329 (w), 1191 (s), 1116 (s), 1080 (s), 1028 (w), 996 (m), 950 (m), 905 
(m), 825 (w), 719 (s), 694 (s) 583 (w), 538 (s) cm-1; 1H NMR (400 MHz, CDCl3): į
3.24 (s, 3H), 3.35 (s, 3H), 4.35 (s, 2H), 4.55 (s, 2H), 5.58 (s, 2H), 7.21-7.32 (m, 5H), 
7.45-7.52 (m, 3H) 7.63-7.67 (m, 2H); 13C NMR (101 MHz, CDCl3): į 52.7, 58.1, 
58.2, 61.6, 65.4, 127.7, 128.4, 128.9, 131.6, 134.8, 143.8; HRMS (ESI): m/z [M+H]+
calcd for C13H18N3O2: 248.1394 found 248.1396. 
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1-(Benzyloxymethyl)-5-phenyl-1H-1,2,3-triazole (28)  
The title compound was prepared from phenyl acetylene (0.102 g, 1 mmol) and 
((azidomethoxy)methyl)benzene (0.179 g, 1.1 mmol) in THF at 65 ˚C. 
Red brown oil; Yield: 90 mg (34%); Rf = 0.50 (Hexanes-EtOAc, 7:3). Analytical data 
were in accordance with those reported in the literature.16
1H NMR (400 MHz, CDCl3): į 4.75 (s, 2H), 5.73 (s, 2H), 7.33-7.37 (m, 5H), 7.48-
7.51 (m, 3H) 7.64-7.66 (m, 2H) 7.83 (s, 1H). 
5.3 Debenzylation of 1-benzyl 1,2,3-triazoles 
General procedure for debenzylation 
Into a solution of 1,2,3-triazole (0.88 mmol) in MeOH (25 ml) was added 10% Pd-C 
(36 mg) and the reaction mixture was affixed with hydrogen balloon (1 atm). After 
removing air, ClCH2CHCl2 (0.128 g, 0.96 mmol) was added. The reaction mixture 
was vigorously stirred at r.t. for 24 hr after which it was filtered through a pad of 
celite. Finally, the filtrate was concentrated to produce the title compound.  
4-(1,1,2,2-Tetraethoxyethyl)-1H-1,2,3-triazole (14) 
The title compound was prepared from 7 (0.181 g, 0.5 mmol) according to the general 
protocol for debenzylation.; Viscous colorless oil; Yield: 0.132 g (97%); Rf = 0.15 
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(hexanes-EtOAc, 7:3); IR: 3217 (br), 2975 (m), 2930 (w), 2890 (w), 1444 (w), 1373 
(w), 1197 (w), 1117 (m), 1080 (s), 961 (m), 924 (w), 861 (w), 808 (w), 762 (w) cm-1; 
1H NMR (400 MHz, CDCl3): į 1.19 (t, J = 7.2 Hz, 12H), 3.27-3.73 (m, 8H), 4.68 (s, 
1H), 7.76 (s, 1H); 13C NMR (101 MHz, CDCl3): į 15.4, 57.7, 65.3, 99.5, 103.2, 
133.0, 135.7; HRMS (ESI): m/z [M+Na]+ calcd for C12H23N3ONa: 296.1581 found 
296.1584. 
2,2-Diethoxy-1-(1H-1,2,3-triazol-4-yl)ethanol (21) 
The title compound was prepared from 22 (0.158 g, 0.54 mmol) according to the 
general protocol for debenzylation. Colorless oil; Yield: 0.105 g (97%); Rf = 0.21 
(hexanes-EtOAc, 7:3); IR: 3147 (br), 2975 (m), 2930 (w), 2895 (w), 1444 (w), 1373 
(w), 1117 (m), 1050 (s), 981 (m), 782 (w) cm-1; 1H NMR (400 MHz, CDCl3): į 1.14 
(t, J = 7.2 Hz, 3H), 1.22 (t, J = 7.2 Hz, 3H), 3.48-3.83 (m, 4H), 4.65 (d, J = 5.6, 1H), 
4.94 (d, J = 6, 1H), 7.73 (s, 1H); 13C NMR (101 MHz, CDCl3): į 15.3, 15.4, 64.1, 
64.5, 67.8, 104.1, 133.8, 148.2; HRMS (ESI): m/z [M+H]+ calcd for C8H16N3O3: 
202.1186 found 202.1185. 
Methyl 1H-1,2,3-triazole-4-carboxylate (15c) 
The title compound was prepared from 15a (0.200 g, 0.92 mmol) according to the 
general protocol for debenzylation. Crystalline solid: Yield: 0.112 g (96%); mp 142.6- 
143.2 ºC; Rf = 0.18 (hexanes-EtOAc, 7:3); IR: 3135 (m), 2935 (m), 1727 (s), 1499 
(m), 1431 (m), 1356 (s), 1242 (m), 1207 (s), 1019 (s), 864 (m), 778(s)  762 (w) cm-1; 
1H NMR (400 MHz, MeOD) į 3.89 (s, 3H), 8.33 (s, 1H); 13C NMR (101 MHz, 
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MeOD) į 51.4, 130.8, 138.6, 161.6; HRMS (ESI): m/z [M+Na]+ calcd for 
C4H5O2N3Na: 150.0274 found  150.0270. 
4-(Methoxymethyl)-1H-1.2.3-triazole (17c) 
The title compound was prepared from 17a (0.175 g, 0.86 mmol) using the general 
protocol for debenzylation. Light yellow oil; Yield: 92 mg (95%); Rf = 0.20 (hexanes-
EtOAc, 7:3); IR: 3132 (br), 2929 (m), 2825 (w), 1450 (m), 1385 (m), 1192 (m), 1087 
(s), 1022 (w), 952 (w), 802 (m), 767 (m) cm-1; 1H NMR (400 MHz, CDCl3): į 3.39 (s, 
3H), 4.61 (s, 2H), 8.71 (s, 1H); 13C NMR (101 MHz, CDCl3): į 58.5, 65.5, 131.2, 
143.8; HRMS (ESI): m/z [M+H]+ calcd for C4H7N3O: 114.0662 found 114.0658. 
4-(Phenoxymethyl)-1H-1,2,3-triazole (18c) 
The title compound was prepared from 1,5-disubstituted 1,2,3-triazole 18b (0.232 g, 
0.88 mmol) according to the general procedure for debenzylation. Colourless crystals; 
Yield: 0.145 g (94%); Rf = 0.50 (hexanes-EtOAc, 7:3). The analytical data were in 
accordance with those reported in the literature.17
1H NMR (500 MHz, MeOD) į 5.19 (s, 1H), 6.94 (ddd, J = 7.5, 4.2, 1.0 Hz, 1H), 7.02 
– 6.98 (m, 2H), 7.30 – 7.24 (m, 2H), 7.87 (s, 1H). 
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4-(Dimethoxymethyl)-1H-1,2,3-triazole (24) 
The title compound was prepared from 19b (0.232 g, 0.89 mmol) according to the 
general protocol for debenzylation. Viscous oil; Yield: 0.120 g (94%); Rf = 0.40 
(hexanes-EtOAc, 7:3); IR: 3137 (br), 2937 (w), 2833 (w), 1447 (w), 1320 (w), 1192 
(m), 1100 (s), 1046 (s), 970 (s), 799 (s) cm-1; 1H NMR (400 MHz, MeOD): į 3.30 (s, 
6H), 5.59 (s, 1H), 7.73 (s, 1H); 13C NMR (101 MHz, CDCl3): į 52.9, 97.9, 130.5, 
144.7; HRMS (ESI): m/z [M+H]+ calcd for C5H10N3O2: 166.0587 found 166.0588.  
1-(1H-1,2,3-triazol-4-yl)ethanol (20c) 
The title compound was prepared from 20a (0.190 g, 0.94 mmol) according to the 
general protocol for debenzylation. Yellow oil; Yield: 0.102 g (96%); Rf = 0. 22 
(hexanes-EtOAc, 1:1); IR: 3145 (br), 2977 (m), 2930 (w), 1697 (s), 1536 (w), 1479 
(w), 1370 (w), 1325 (w), 1234 (w), 1051 (s), 965 (w), 925 (w), 827 (m), 681(m) cm-1; 
1H NMR (400 MHz, CDCl3): į 1.47 (d, J = 6.4 Hz, 3H), 4.93-4.98 (q, J = 6.4 Hz, 
1H), 7.65 (s, 1H); 13C NMR (101 MHz, CDCl3): į 22.6, 62.6, 126.6, 149.9; HRMS 
(ESI): m/z [M+H]+ calcd for C4H8N3O: 114.0666 found 114.0659. 
4-(Diethoxymethyl)-1H-1,2,3-triazole (19c) 
The title compound was prepared from 19a (0.248 g, 0.95 mmol) using the general 
protocol for debenzylation with EtOH as the solvent. Viscous oil; Yield 0.157 g 
(97%); Rf = 0.19 (hexanes-EtOAc, 7:3); IR: 3134 (br), 2976 (w), 2884 (w), 1445 (w), 
1340 (w), 1103 (m), 1053 (s), 974 (w), 805 (w) cm-1; 1H NMR (400 MHz, CDCl3): į
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1.25 (t, J = 6.8 Hz, 3H), 3.60-3.69 (m, 4H), 5.76 (s, 1H), 7.76 (s, 1H); 13C NMR (101 
MHz, CDCl3): į 15.4, 61.8, 96.5, 134.3, 148.1; HRMS (ESI): m/z [M+Na]+ calcd for 
C7H13N3O2Na: 194.0900 found 194.0905. 
1H-1,2,3-triazole-4-carbaldehyde (25) 
While sitting in open air, 24 (0.120 g, 0.84 mmol) decomposed to give the title 
compound. Yellow crystalline solid; Yield 94 mg (97%); m.p 135.9- 136.5 ºC; IR: 
3170 (br), 3126 (m), 2889 (w), 1693 (m), 1668 (s), 1530 (w), 1454 (w), 1399 (m), 
1322 (s), 1237 (s), 1108 (m), 1028 (m), 829 (s), 764 (s), 636 (s) cm-1; 1H NMR (400 
MHz, MeOD) į 10.17, 11.58; 13C NMR (101 MHz, MeOD) į 127.8, 139.4, 194.75; 
HRMS (ESI): m/z [M+Na]+ calcd for C3H3N3ONa: 120.0163 found 120.0168. 
2,2-Diethoxy-1-(1H-1,2,3-triazol-4-yl)ethanone (23) 
To a solution of NH-1,2,3-triazole 14 (0.119 g, 0.43 mmol) in a mixture of acetone (9 
ml) and water (0.5 ml) was added Dowex 50W (16-40 mesh, 0.170 g). The mixture 
was heated at reflux for 6 hr before the Dowex resin was removed by filtration and 
acetone was removed The aqueous layer was extracted with CH2Cl2 (3 x 5 ml) and 
thecombined organic layers were dried over MgSO4. The drying agent was removed 
by filtration and the filtrate was concentrated. The crude product was purified using 
flash column chromatography (hexanes-EtOAc, 7:3) to give the title compound. 
Yellow oil; Yield: 79 mg (93%); Rf = 0.22 (hexane-EtOAc 7:3); IR: 3145 (br), 2977 
(m), 2930 (w), 1697 (s), 1536 (w), 1479 (w), 1370 (w), 1325 (w), 1234 (w), 1051 (s), 
965 (w), 925 (w), 827 (m), 681(m) cm-1; 1H NMR (400 MHz, CDCl3): į 1.24 (t, J = 
7.2 Hz, 6H), 3.68-3.81 (m, 4H), 5.38 (s, 1H), 8.49 (s, 1H); 13C NMR (101 MHz, 
128
CDCl3): į 15.3, 63.8, 101.3, 133.0, 142.3, 187.8; HRMS (ESI): m/z [M+H]+ calcd for 
C8H14N3O3: 200.1030 found 200.1033. 
5.4 Synthesis of piperidine based building blocks 
Ethyl 2-(2-oxopyrrolidin-1-yl)acetate (31) 
1 2
&2(W
The title compound was prepared in 73% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.18
1H NMR (400 MHz, CDCl3): į 1.28 (t, J = 7.3, 3H), 2.02-2.12 (m, 2H), 2.39 (t, 2H, J
= 8), 3.50 (t, J = 7, 2H), 4.05 (s, 2H) 4.19 (q, J = 7, 2H). 
4-(Carboxymethylamino)butanoic acid hydrochloride (33) 
The title compound was prepared in 90% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.18
1H NMR (400 MHz, D2O): į 1.58-172 (m, 2H), 2.21 (t, J = 7.2, 2H), 2.86 (t, J = 7.8, 
2H), 3.67 (s, 2H). 
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Methyl 4-(2-methoxy-2-oxoethylamino)butanoate hydrochloride (33) 
The title compound was prepared in 75% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.18
1H NMR (400 MHz, MeOD): į 2.01- 2.16 (m, 2H), 2.57 (t, J = 7.2, 2H), 3.15-3.25 
(m, 2H), 3.71 (s, 3H), 3.87 (s, 3H), 4.10 (s, 2H), 5.48 (s, 1H).  
Methyl 4-(tert-butoxycarbonyl(2-methoxy-2-oxoethyl)amino)butanoate (34) 
The title compound was prepared in 92% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.18
. 1H NMR (400 MHz, CDCl3): į 1.23 (s, 9H), 1.55-1.58 (m, 2H), 2.15 (t, J = 7.3, 2H), 
3.13 (t, J = 6.8, 2H), 3.46 (s, 3H), 3.46 (s, 3H), 3.52 (s, 3H), 3.70 (s, 2H). 
1-tert-Butyl 4-methyl 3-oxopiperidine-1,4-dicarboxylate (35) 
1%RF
2
&20H
The title compound was received in only 28% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.18
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1H NMR (CDCl3): į 1.47 (s, 9H), 2.32-2.40 (m, 2H), 3.49 (t, J = 6, 2H), 3.78 (s, 3H), 
4.03 (s, 2H), 12.00 (s, 1H).  
1-tert-Butyl 4-methyl 3-oxopiperidine-1,2-dicarboxylate (36) 
The title compound was received in only 36% yield according to already published 
procedure. The spectroscopic data were in agreement with literature.18
1H-NMR (400 MHz, CDCl3): į 1.49 (s, 9H), 1.81-2.08 (m, 2H), 2.41-2.60 (m, 2H), 
3.28-3.45 (m, 1H), 3.79 (s, 3H), 3.86-4.10 (m, 1H), 5.06 (s, 1H), 5.22 (s, 1H), 11.12 
(s, 1H). 
Ethyl 3-oxopiperidine-4-carboxylate hydrochloride (38) 
1+
&2(W
2
+&O
A mixture of ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride (37) 
(10.395 g, 35.0 mmol), and 10% Pd-C (1.050 g) in methanol (350 ml) was affixed 
with hydrogen balloon (1 atm). Air was removed and ClCH2CHCl2 (3.23 ml, 35.0 
mmol) was added. The solution was vigorously stirred at r.t. for 2 hr. The Pd-C 
catalyst was filtered off through a pad of celite. The filtrate was concentrated, residue 
was diluted with diethyl ether and evaporated to give 38 (7.443 g, 99%) as off-white 
crystalline solid; 1H NMR (400 MHz, CDCl3) į 1.29 (t, J = 7.2 Hz, 3H), 2.33 (t, J = 
5.8 Hz, 2H), 2.58 (t, J = 5.8 Hz, 2H), 3.10 (s, 2H), 3.60 (s, 2H), 4.22 (q, J = 7.1 Hz, 
2H), 11.92 (s, 1H). The spectroscopic data were in agreement with literature 19  
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1-tert-Butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (39) 
1%RF
&2(W
2
A mixture of 38 (7.045 g, 34.0 mmol) in 10% aq. Na2CO3 (30 ml) was cooled to 0 ˚C 
and di-tert-butyl dicarbonate (8.153 g, 37.4 mmol) was added in portions. The stirring 
was continued at 0 ˚C for 1 hr and then at r.t for overnight. The reddish brown 
mixture was extracted with diethyl ether (50 ml x 3). The combined extracts were 
washed with brine, dried over anhydrous MgSO4 and concentrated. Purification of the 
crude product with flash column chromatography using (hexane-EtOAc, 9:1) gave 39
(7.859 g, 85%) as yellow oil. 
1H NMR (400 MHz, CDCl3) į 1.28 (t, J = 7.1 Hz, 3H), 1.44 (s, 9H), 2.30 (d, J = 5.4 
Hz, 2H), 3.46 (t, J = 5.7 Hz, 2H), 4.00 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 12.05 (s, 1H). 
The spectroscopic data were in agreement with literature.19  
1-tert-Butyl 4-ethyl 3-hydroxopiperidine-1,4-dicarboxylate (40) 
1%RF
&2(W
2+
A solution of 39 (7.737 g, 28.5 mmol) in methanol (140 ml) was cooled to -12 ˚C and 
NaBH4 (1.097 g, 29.0 mmol) was added slowly over 10 min. After 1 hr, the reaction 
was quenched by slow addition of 10% citric acid (25 ml) and stirring was continued 
for 10 min at -10 ˚C and for 10 min at r.t. The aqueous layer was extracted with 
chloroform (50 ml x 3). The combined organic layers were washed with brine, dried 
over anhydrous MgSO4 and concentrated. Purification of the crude product with flash 
column chromatography using (hexane-EtOAc, 7:3) gave 40 as an inseprable mixture 
of isomers (7.527 g, 96%); Clear oil; Rf = 0.44; HRMS (ESI): m/z [M+Na]+ calcd 
C13H23O5NNa: 296.1468 found 296.1469.  
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trans-1-tert-Butyl 4-ethyl 3-(tert-butyldimethylsilyloxy)piperidine-1,4-
dicarboxylate (trans-41) 
(A). A solution of 40 (obtained from exp. 4, see Table 3.1) (5.30 g, 19.56 mmol) in 
DMF (50 ml) was treated with imidazole (8.843 g, 58.68 mmol) and TBSCl (4.389 g, 
64.55 mmol) at r.t. After 2 hr, 10% citric acid (20 ml) was added into the solution 
before extraction with EtOAc (30 ml x 3). The combined organics were washed with 
brine, dried over anhydrous MgSO4 and concentrated. Purification of the crude 
product with flash column chromatography using (hexane-EtOAc, 9:1) gave trans-41
(0.580 g, 8%), cis-41 (5.440 g, 72%), trans-42 (1.588 g, 18%) and a fraction of cis-
42.  
Method (B). A solution of 40 (obtained from exp. 2, see Table 3.1) (7.520 g, 27.55 
mmol) in DMF (50 ml) was treated with imidazole (6.175 g, 90.81 mmol) and TBSCl 
(12.408 g, 82.72 mmol) at r.t. After 4 hr, 10% citric acid (35 ml) was added into the 
solution before extraction with EtOAc (40 ml x 3). The combined organics were 
washed with brine, dried over anhydrous MgSO4 and concentrated. Purification of the 
crude product with flash column chromatography using (hexane-EtOAc, 9:1) gave 
trans-41 (1.470 g, 14%) and cis-41 (7.265 g, 68%).  
For trans-41; Clear oil; Rf = 0.34; IR: 2959 (w), 2929 (m), 2896 (w), 2855 (m), 1735 
(s), 1692 (s), 1463 (w), 1426 (s), 1363 (s), 1307 (m), 1243 (s), 1161 (s), 1124 (s), 
1093 (w), 1032 (s), 932 (m), 829 (s), 775 (s), 699 (w) cm-1; 1H NMR (400 MHz, 
CDCl3) į 0.02 – 0.22 (m, 6H), 0.84 (s, 9H), 1.25 (t, J = 7.2 Hz, 3H), 1.45 (s, 9H), 1.60 
– 1.64 (m, 1H), 1.82 (dd, J = 8.0 Hz, 1H), 2.35 – 2.46 (m, 1H), 2.56 (s, 1H), 2.67 (t, J
= 12.0 Hz, 1H), 3.79 (s, 1H), 4.05 (d, J = 6.1 Hz, 1H), 4.10 – 4.14 (m, 2H); 13C NMR 
(101 MHz, CDCl3) į -5.1, 14.3, 17.9, 25.6, 25.7, 25.8, 27.6, 28.5, 42*, 49*, 51.1, 
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60.7, 68.7, 79.9, 154.5, 173.9; HRMS (ESI): m/z [M+Na]+ calcd C19H37NO5NaSi: 
410.2333 found 410.2335. 
cis-1-tert-Butyl 4-ethyl 3-(tert-butyldimethylsilyloxy)piperidine-1,4-dicarboxylate 
(cis-41) 
See description of synthesis of trans-41 for experimental details. For cis-41; Clear oil; 
Rf = 0.22; ; IR: 2959 (w), 2929 (m), 2896 (w), 2855 (m), 1735 (s), 1692 (s), 1463 (w), 
1426 (s), 1363 (s), 1307 (m), 1243 (s), 1161 (s), 1124 (s), 1093 (w), 1032 (s), 932 
(m), 829 (s), 775 (s), 699 (w) cm-1; 1H NMR (400 MHz, CDCl3) į  0.03 – 0.06 (m, 
6H), 0.86 (s, 9H), 1.25 (t, J = 7.0 Hz, 3H), 1.44 (s, 9H), 1.57 – 1.80 (m, 2H), 2.07 (qd, 
J = 8.2, 1H), 2.37 – 2.58 (m, 1H), 2.60 – 3.03 (m, 1H), 3.91 – 4.39 (m, 1H); 13C NMR 
(101 MHz, CDCl3) į 1.2, 14.3, 17.9, 21.7, 25.8, 28.5, 42*,47.1, 49*, 60.6, 66.6, 79.9, 
154.5, 172.2; HRMS (ESI): m/z [M+Na]+ calcd C19H38NO5Si: 388.2519 found 
388.2504.  
trans-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-((tert-
butyldimethylsilyloxy)methyl)piperidine-1-carboxylate (trans-42) 
1%RF
27%'06
27%'06
  WUDQV
See description of synthesis of trans-41 for experimental details. For trans-42; Clear 
oil; Rf = 0.89; IR: 2954 (w), 2928 (w), 2856 (w), 1698 (s), 1471 (w), 1364 (m), 1251 
(m), 1169 (m), 1090 (s), 936 (m), 831 (s), 772 (s), 668 (m) cm-1; 1H NMR (400 MHz, 
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CDCl3) į 0.07 – 0.18 (m, 12H), 0.86 (s, 18H), 1.19 – 1.37 (m, 1H), 1.44 (s, 9H), 1.59 
– 1.72 (m, 1H), 2.48 (br s, 1H), 2.55 – 2.61 (s, 1H), 3.38 (d, J = 4.0 Hz, 1H), 3.56 (dd, 
J = 7.2 Hz, 1H), 3.67 (br s, 1H), 3.90–  4.04 (m, 2H); 13C NMR (101 MHz, CDCl3) į
18.1, 18.4, 25.9, 26.8, 27.2, 28.5, 44*, 46.6, 51*, 63.4, 67.9, 79.5, 154.8; HRMS 
(ESI): m/z [M+Na]+ cald for C23H49O4NNaSi2 : 482.3092 found 482.3096. 
cis-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-((tert-
butyldimethylsilyloxy)methyl)piperidine-1-carboxylate (cis-42)
1%RF
27%'06
27%'06
  FLV
See description of synthesis of trans-41 for experimental details for method A. 
Method (B): A solution of cis-46 (0.102 g, 0.30 mmol) in DMF (2 ml) was treated 
with imidazole (67 mg, 0.99 mmol) and TBSCl (0.136 g, 0.90 mmol) at r.t. After 1 hr, 
10% citric acid (2 ml) was added into the solution before extraction with EtOAc (5 ml 
x 3). The combined organics were washed with brine, dried over anhydrous MgSO4
and concentrated. Purification of the crude product with flash column 
chromatography using (hexane-EtOAc, 7:3) gave cis-42 (0.120 g, 87%); Rf = 0.55; 
Crystalline solid; mp 57.8- 59.3 ºC; IR: 2952 (w), 2926 (w), 2854 (w), 1681 (s), 1430 
(m), 1363 (m), 1247 (m), 1169 (m), 1096 (m), 983 (w), 939 (w), 831 (s), 785 (s), 665 
(w) cm-1; 1H NMR (400 MHz, CDCl3) į -0.49 – -0.51 (m, 12H), 0.35 (s, 18H), 0.79 – 
0.86 (m, 1H), 0.90 (s, 9H), 1.02 – 1.10 (m, 2H), 2.08 – 2.21 (m, 1H), 2.20 – 2.26 (m, 
1H), 2.78 – 2.87 (m, 1H), 3.03 – 3.10 (m, 1H), 3.34 (d, J = 10.9 Hz, 1H), 3.40 – 3.47 
(m, 1H), 3.56 – 3.66 (m, 1H); 13C NMR (101 MHz, CDCl3) į 0.1, 18.5, 22.6, 26.1, 
28.6, 44.1, 50.5, 64.4, 79.5, 155.4; HRMS (ESI): m/z [M+Na]+ cald for 
C23H49O4NNaSi2 : 482.3092 found 482.3100. 
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cis and trans-1-(tert-Butoxycarbonyl)-3-(tert-butyldimethylsilyloxy)piperidine-4-
carboxylic acid (43) 
1%RF
&22+
27%'06
  
Method A: Into a solution of cis-41 (5.406 g, 13.97 mmol) in EtOH (15 ml), 
NaOEt/EtOH 21 wt % (5.5 ml, 69.9 mmol) was added and heated to 70 ºC for 2 hr. 
NaOH (5.588, 139.6 mmol) was then added and stirred for 4 additional hr. Most of 
the EtOH was evaporated and EtOAc (5 ml) was added. At 0 ºC, 10% citric acid (5 
ml) was added and extraction was done with EtOAc (10 ml x 3). The pH of aqueous 
layer was maintained to 2-3 with 0.5 M HCl solution. The combined organics were 
washed with brine, dried over anhydrous MgSO4 and concentrated. Purification of the 
crude product with flash column chromatography using (hexane-EtOAc, 7:3) gave 43 
(0.920 g, 18%), 44 (0.996 g, 29%) and 45 (0.160 g, 5%).  
Method B: Into a solution of cis-41  (0.201 g, 0.52 mmol) in EtOH (5 ml), 
NaOEt/EtOH 21 wt % (0.2 ml, 2.6 mmol) was added under nitrogen and heated to 70 
ºC for 2 hr. NaOH (2M, 1.5 ml, 2.6 mmol) was then added and stirred for 2 additional 
hr. Most of the EtOH was evaporated and EtOAc (5 ml) was added. At 0 ºC, 10% 
citric acid (5 ml) was added and extraction was done with EtOAc (10 ml x 3). The pH 
of aqueous layer was maintained to 5 with 0.5 M HCl solution. The combined 
organics were washed with brine, dried over anhydrous MgSO4 and concentrated. 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 7:3) gave 43 (0.138 g, 74%) and 44 (27 mg, 21%).  
For 43; Yellow oil; Rf = 0.36; IR: 3153 (w), 2929 (w), 2856 (w), 1737 (w), 1697(s), 
1425 (m), 1366 (m), 1249 (m), 1158 (s), 1112 (m), 1005 (w), 959 (w), 890 (s), 774 (s) 
cm-1; 1H NMR (400 MHz, CDCl3) į 0.02 – 0.28 (m, 6H), 0.83 – 0.96 (m, 9H), 1.26 (s, 
1H), 1.46 (s, 9H), 1.65 (s, 1H), 1.96 – 2.19 (m, 1H), 2.46 (d, J = 8.5 Hz, 1H), 2.52 – 
2.88 (m, 2H), 2.99 – 3.39 (m, 1H), 3.67 – 3.73 (m, 1H), 3.93 –  4.37 (m, 1H); 13C 
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NMR (101 MHz, CDCl3) į -5.0, 18.0, 25.8, 27.4, 28.5, 42*, 46.4, 49*,  50.7, 68.5, 
80.2, 154.5, 177.5; HRMS (ESI): m/z [M+Na]+ calcd C17H33O5NNaSi : 382.2020 
found 382.2024. 
cis and trans-1-(tert-Butoxycarbonyl)-3-hydroxypiperidine-4-carboxylic acid (44) 
1%RF
&22+
2+
  
See description of synthesis of 43 for experimental details. For 44; Yellow oil; IR: 
3359 (w), 2976 (w), 2930 (w), 1661(s), 1417 (m), 1365 (m), 1239 (m), 1158 (s), 1129 
(s), 1046 (w) 885 (w), 767 (w) cm-1; 1H NMR (400 MHz, MeOD) į 1.27 (s, 9H), 1.75 
(dd, J = 8.2, 1H), 2.07 – 2.22 (m, 1H), 2.31 – 2.41 (m, 1H), 2.57 (br s, 1H), 3.45 – 
3.55 (m, 1H), 3.76 – 3.81 (m, 1H), 3.83 – 3.95 (t, J = 13.8 Hz, 1H); 13C NMR (101 
MHz, CDCl3) į 23.8, 28.9, 43.7, 46.8, 51.4, 68.8, 81.5, 156.5, 178.8; HRMS (ESI): 
m/z [M-H]- calcd for C11H18O5N: 244.1192 found 244.1190.  
1-(tert-Butoxycarbonyl)-1,2,3,6-tetrahydropyridine-4-carboxylic acid (45) 
1%RF
&22+
  
See description of synthesis of 43 for experimental details. For 45; thick oil; 1H NMR 
(400 MHz, MeOD) į 1.17 – 1.33 (m, 1H), 1.48 (s, 9H), 1.98 (d, J = 5.3 Hz, 1H), 2.06 
– 2.23 (m, 1H), 3.17 (s, 1H), 3.46 – 3.73 (m, 2H), 3.99 – 4.21 (m, 1H), 4.83 – 5.06 
(m, 1H), 6.82 – 6.94 (m, 1H); 13C NMR (101 MHz, MeOD) į 23.9, 28.4, 37.4, 39.5, 
81.4, 101.1, 127.5, 154.9, 171.3; HRMS (ESI): m/z [M+Na]+ calcd C11H17O4NNa: 
250.1050 found 250.1053.  

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trans-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-(hydroxymethyl)piperidine-1-
carboxylate (trans-46) 
1%RF
27%'06
2+
  WUDQV
(Method A): A solution of trans-41 (0.356 g, 09 mmol) in dry THF (5 ml) was treated 
with slow addition of LiAlH4 (3 ml) at -35 ˚C. After 40 min, saturated solution of 
Rochelle’s salt (10 ml) was added and stirring was continued for overnight at r.t. 
After extraction with EtOAc (10 ml x 3), organic layer was washed with brine, dried 
with MgSO4 and concentrated. Purification of the crude product with flash column 
chromatography using (hexane-EtOAc, 7:3) gave trans-46 (227 mg, 72%).  
(Method B): Into solution of borane dimethylsulfoxide complex (0.1 ml, 1.06 mmol) 
in dry THF (2 ml) 43 (0.190 g, 0.53 mmol dissolved in 3 ml dry THF) was added 
dropwise in 10 min and refluxed for 4 hr. Then cooled to r.t. and MeOH (3 ml) was 
added and solvent was removed under reduced pressure. The concentrated organic 
was redissolved in MeOH (5 ml x 2) and concentrated. Purification of the crude 
product with flash column chromatography using (hexane-EtOAc, 8:2) gave trans-46
(0.114 g, 62%) and cis-46 (58 mg, 32%). For trans-46; Crystalline solid; Rf = 0.56; 
IR: 3453 (s), 2957 (w), 2926 (m), 2854 (m), 1667 (s), 1470 (w), 1434 (m), 1365 (s), 
1291 (s), 1255 (s), 1140 (s), 1076 (m), 1064 (m), 863 (s), 790 (s), 666 (w) cm-1; 1H 
NMR (400 MHz, CDCl3) į 0.13 (s, 6H), 0.90 (s, 9H), 1.18 – 1.32 (m, 2H), 1.45 (s, 
9H), 1.58 – 1.80 (m, 2H), 2.57 (m, 1H), 3.42 (s, 1H), 3.48 – 3.80 (m, 2H), 4.11 (br s, 
2H); 13C NMR (101 MHz, CDCl3): į -4.8, 18.0, 25.9, 27.1, 28.6, 43*, 46.4, 51*, 65.9, 
71.7, 79.8, 154.6; HRMS (ESI): m/z [M+Na]+ calcd for C17H35NO4NaSi: 368.2228 
found 368.2229.  
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cis-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-(hydroxymethyl)piperidine-1-
carboxylate (cis-46) 
1%RF
27%'06
2+
  FLV
See description of synthesis of trans-46 by method B for experimental details. For cis-
46; Clear oil; Rf = 0.38 (Hexanes-EtOAc, 8:2) ; IR: 3440 (s), 2957 (w), 2928 (m), 
2855 (m), 1668 (s), 1462 (w), 1428 (s), 1365 (m), 1247 (s), 1165 (s), 1129 (m), 1091 
(m), 1064 (m), 1032 (s), 935 (m), 835 (s), 713 (s), 732 (w) cm-1; 1H NMR (400 MHz, 
CDCl3) į 0.02 (s, 6H), 0.83 (s, 9H), 1.38 (s, 9H), 1.47 – 1.86 (m, 2H), 2.18 (s, 1H), 
2.69 – 2.98 (m, 2H), 3.48 (s, 1H), 3.62 (dd, J = 8.5 Hz, 1H), 3.78-4.02 (m, 3H); 13C 
NMR (101 MHz, CDCl3) į -4.5, 18.1, 23.0, 25.9, 28.5, 42.4, 42.8, 49.8, 64.1, 66.5, 
79.6, 155.3; HRMS (ESI): m/z [M+Na]+ calcd for C17H35NO4NaSi: 368.2228 found 
100%.  
trans-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-(tosyloxymethyl)piperidine-1-
carboxylate (trans-47) 
1%RF
27%'06
27V
  WUDQV
Into solution of trans-46 (1.014 g, 2.94 mmol) in pyridine (6 ml), TsCl (0.673 g, 3.53 
mmol) was added at 0 ºC and stirred for 4 hr, shifted to r.t. and stirred up to 48 hr. 
Then MeOH (10 ml) was added, stirred for 10 min and concentrated. After extraction 
with DCM (15 ml x 3), organic layer was washed with brine, dried with MgSO4 and 
concentrated. Purification of the crude product with flash column chromatography 
using (hexane-EtOAc, 7:3) gave trans-47 (1.002 g, 68%); Thick oil; Rf = 0.38; IR; 
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2954 (w), 2928 (m), 2851 (m), 1692 (s), 1590 (w), 1419 (m), 1363 (s), 1252 (m), 
1236 (w), 1174 (s), 1083 (w), 963 (m), 833 (s), 774 (s), 665 (s), 553 (s) cm-1; 1H 
NMR (400 MHz, CDCl3) į 0.05 (s, 6H), 0.79 (s, 9H), 1.29 (m , 1H), 1.44 (s, 9H), 
1.58-1.75 (m, 2H), 2.43 (s, 4H), 2.57 (m, 1H), 3.26 – 3.37 (m, 1H), 3.89 – 4.20 (m, 
4H), 7.32 (d, J = 8.2 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H); 13C NMR (101 MHz, CDCl3) 
į 0.1, 17.9, 21.7, 25.7, 27.0, 28.5, 43*, 44.0, 51*, 67.6, 70.8, 79.9, 128.0, 129.9, 
132.8, 144.9, 154.4; HRMS (ESI): m/z [M+Na]+ calcd for C24H41NO6NaSSi: 
522.2316 found 522.2307. 
cis-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-(tosyloxymethyl)piperidine-1-
carboxylate (cis-47) 
1%RF
27%'06
27V
  FLV
Into solution of cis-46 (0.315 g, 0.91 mmol) in pyridine (3 ml), TsCl (0.209 g, 1.09 
mmol) was added at 0 ºC and stirred for 4 hr, shifted to r.t and stirred up to 48 hr. 
Then MeOH (5 ml) was added, stirred for 10 min and concentrated and water was 
added (5 ml). After extraction with DCM (10 ml x 3), organic layer was washed with 
brine, dried with MgSO4 and concentrated. Purification of the crude product with 
flash column chromatography using (hexane-EtOAc, 8:2) gave cis-47 (0.240 g, 53%); 
Clear oil; Rf = 0.62; IR: 2928 (w), 2855 (w), 1688 (s), 1426 (m), 1362 (s), 1250 (m), 
1173 (s), 1141 (s), 1096 (m), 972 (m), 829 (s), 773 (s), 664 (s) cm-1; 1H NMR (400 
MHz, CDCl3) į -0.03 (s, 3H), 0.07 (s, 1H), 0.80 (s, 9H), 1.19 – 1.33 (m, 1H), 1.41 (s, 
9H), 1.43 – 1.49 (m, 1H), 1.86 (m, 1H), 2.43 (s, 3H), 2.55 – 2.85 (m, 2H), 3.82 (br s, 
1H), 3.92 –  4.00 (m, 2H), 4.05 – 4.21 (m, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 
8.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) į 18.0, 21.7, 22.2, 25.8, 28.5, 40.7, 42.2, 
49.8, 64.6, 71.2, 79.8, 128.0, 129.9, 132.9, 144.9, 155.2; HRMS (ESI): m/z [M+Na]+
cald for C24H41O6NNaSSi: 522.2316 found 522.2321.  
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trans-tert-Butyl 4-(azidomethyl)-3-(tert-butyldimethylsilyloxy)piperidine-1-
carboxylate (trans-48) 
1%RF
27%'06
1
  WUDQV
A mixture of trans-47 (0.558 g, 1.12 mmol) and NaN3 (0.218 g, 3.36 mmol) in dry 
DMF (5 ml) was stirred under N2 for 8hr at 65 ˚C. Water (5 ml) was added to the 
reaction mixture and the product was extracted with diethyl ether (10 ml x 3). The 
organic layer was washed, dried with anhydrous MgSO4 and concentrated. 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 8:2) gave trans-48 ( 0.412 g, 99%) as thick oil; Rf = 0.80; IR; 2955 (w), 2929 
(m), 2857 (s), 2096 (s), 1694 (s), 1417 (s), 1365 (s), 1249 (m), 1163 (s), 1141 (s), 
1081 (s), 960 (s), 868 (w), 832 (s), 774 (s), 667 (w) cm-1; 1H NMR (400 MHz, CDCl3) 
į 0.10 (s, 6H), 0.90 (s, 9H), 1.40 – 1.24 (m, 2H), 1.45 (s, 9H), 1.70 – 1.80 (m, 1H), 
2.47 (s, 1H), 2.63 (s, 1H), 3.33 (dd, J = 9.2 Hz, 2H), 3.52 (dd, J = 7.2 Hz, 1H), 4.12 
(s, 2H); 13C NMR (101 MHz, CDCl3) į -4.8, 18.1, 25.9, 27.9, 28.6, 43*, 44.6, 51*, 
53.3, 68.8, 79.9, 154.5; HRMS (ESI): m/z [M+Na]+ calcd for C17H34O3N4NaSi: 
393.2292 found 393.2293. 
cis-tert-Butyl 4-(azidomethyl)-3-(tert-butyldimethylsilyloxy)piperidine-1-
carboxylate (cis-48) 
1%RF
27%'06
1
  FLV
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A mixture of cis-47 (0.212 g, 0.42 mmol) and NaN3 (82 mg, 1.26 mmol) in dry DMF 
(5 ml) was stirred under N2 for 16 hr at 65 ˚C. Then cooled to r.t., water (3 ml) was 
added to the reaction mixture and the product was extracted with diethyl ether (5 ml x 
3). The organic layer was washed, dried with anhydrous MgSO4 and concentrated. 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 8:2) gave cis-48 (0.141 g, 91%); Clear oil; Rf = 0.55 (8:2); IR; 2928 (w), 
2855 (m), 2096 (s), 1690 (s), 1426 (s), 1364 (s), 1243 (s), 1168 (s), 1133 (s), 1094 
(w), 1039 (m), 985 (w), 837 (s), 776 (s) cm-1; 1H NMR (400 MHz, CDCl3) į 0.06 (s, 
6H), 0.87 (s, 9H), 1.43 (s, 9H), 1.51 – 1.70 (m, 2H), 2.68 – 2.74 (m, 1H), 2.74 – 2.80 
(m, 1H), 3.15 – 3.21 (m, 1H), 3.25 – 3.31 (m, 1H), 3.78 – 3.83 (m, 1H), 3.89 – 4.09 
(m, 1H), 4.16 (t, J = 14.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) į 18.2, 23.6, 25.9, 
28.6, 41.1, 42.6, 50.1, 53.3, 65.3, 79.8, 155.3; HRMS (ESI): m/z [M+Na]+ cald for 
C17H34O3N4NaSi: 393.2292 found 393.2288. 
trans-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-((4-phenyl-1H-1,2,3-triazol-1-
yl)methyl)piperidine-1-carboxylate (49)
1%RF
27%'06
1 1
1
3K
  
A mixture of trans-48 (0.250 g, 0.68 mmol), phenyl acetylene (0.108 g, 1.02 mmol), 
CuSO4 .5H2O (6 mg, 0.02 mmol) and Na-ascorbate (15 mg, 0.07 mmol) in 
dioxane/water (4 ml, 3:1) was stirred for overnight at 65 ºC. The extraction was done 
with ethyl acetate (10 ml x 3). The combined organics were washed with brine, dried 
over anhydrous MgSO4 and concentrated. Purification of the crude product with flash 
column chromatography using (hexane-EtOAc, 8:2) gave 49 (0.295 g, 93%); White 
powdery solid; mp 174-175 ºC; Rf = 0.55; IR: 2929 (w), 2855 (w), 1728 (s), 1681 (s), 
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1463 (w), 1426 (m), 1365 (m), 1241 (s), 1156 (s), 1074 (m), 833 (s), 778 (m), 763 (s), 
693 (m) cm-1; 1H NMR (400 MHz, CDCl3) į 0.17 (s, 6H), 0.95 (s, 9H), 1.23 – 1.27 
(m, 2H), 1.44 (s, 9H), 1.98 – 2.04 (m, 1H), 2.50 – 2.56 (m, 2H), 3.38 – 3.41 (m, 1H), 
4.04 (s, 1H), 4.22 (dd, J = 11.5, Hz, 2H), 4.73 (dd, J = 8.1 Hz, 1H), 7.33 (t, J = 7.4 
Hz, 1H), 7.43 (t, J = 7.5 Hz, 2H), 7.72 (s, 1H), 7.83 (d, J = 7.1 Hz, 2H); 13C NMR 
(101 MHz, CDCl3) į -3.4, 19.4, 27.2, 29.7, 43*, 46.9, 51*, 53.5, 71.0, 81.3, 121.2, 
127.0, 129.5, 130.2, 131.8, 149.2; HRMS (ESI): m/z [M+Na]+ calcd for 
C25H40O3N4NaSi: 495.2762 found 495.2765.  
trans-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-((4-methoxycarbonyl-1H-1,2,3-
triazol-1-yl)methyl)piperidine-1-carboxylate (50) 
1%RF
27%'06
1 1
1
  
2
2
A mixture of trans-48 (0.408 g, 1.1 mmol), methyl propiolate (0.139 g, 1.65 mmol), 
CuSO4 .5H2O (10 mg, 0.04 mmol) and Na-ascorbate (23 mg, 0.12 mmol) in 
dioxane/water (4 ml, 3:1) was stirred for 12 hr at 65 ºC. The extraction was done with 
ethyl acetate (10 ml x 3). The combined organics were washed with brine, dried over 
anhydrous MgSO4 and concentrated. Purification of the crude product with flash 
column chromatography using (hexane-EtOAc, 7:3) gave 50 (0.479 g, 96%); White 
solid; mp 141-142.5 ºC; Rf = 0.29 (Hex/EtOAc, 7:3); IR: 3130 (w), 2974 (w), 2930 
(w), 2861 (w), 1728 (m), 1688 (m), 1423 (m), 1365 (m), 1227 (m), 1155 (s), 1125 
(m), 1042 (s), 954 (m), 872 (m), 775 (m) cm-1; 1H NMR (400 MHz, CDCl3) į 0.13 (s, 
6H), 0.91 (s, 9H), 1.13 – 1.26 (m, 2H), 1.43 (s, 9H), 1.78-2.02 (m, 1H), 2.40 – 2.53 
(m, 2H), 3.36 (dt, J = 7.4 Hz, 1H), 3.94 (s, 3H), 4.06 (br s, 1H), 4.23 (dd, J = 11.5 Hz, 
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2H), 4.72 (dd, J = 8.2 Hz, 1H), 8.05 (s, 1H); 13C NMR (101 MHz, CDCl3) į 18.1, 
25.9, 27.7, 28.5, 43*, 45.6, 50*, 52.3, 52.6, 69.8, 80.1, 128.0, 140.1, 154.3, 161.2; 
HRMS (ESI): m/z [M+Na]+ calcd for C21H38O5N4NaSi: 477.2504; found 477.2506. 
trans-tert-Butyl 3-hydroxy-4-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)piperidine-
1-carboxylate (51) 
1%RF
2+
1 1
1
3K
  
Into a solution of 49 (0.285 g, 0.60 mmol) in dry THF (6 ml), TBAF (0.35 ml, 1.20 
mmol) was added slowly and stirred for 12 hr. Then water (5 ml) was added and 
extraction was done with ethyl acetate (10 ml x 3). The organic phase was washed 
with brine, dried over with anhydrous MgSO4 and concentrated under reduced 
pressure. Purification of the crude product with flash column chromatography using 
(hexane-EtOAc, 7:3) gave 51 (0.208 g, 97%); Crystalline solid; mp 179-180 ºC; Rf = 
0.58; IR: 3408 (br), 3188 (w), 2871 (w), 1726 (m), 1672 (s), 1425 (m), 1365 (m), 
1245 (m), 1160 (m), 1059 (w), 954 (w), 882 (m), 765 (m) cm-1; 1H NMR (400 MHz, 
CDCl3) į 1.28 (dt, J = 10.3, Hz, 1H), 1.42 (s, 9H), 1.64 (d, J = 12.1 Hz, 1H), 1.95 (d, 
J = 5.9 Hz, 1H), 2.59 – 2.62 (m, 1H), 3.36 (s, 1H), 3.54 – 3.75 (m, 2H), 4.02 (s, 1H), 
4.32 (s, 1H), 4.54 (s, 1H), 4.67 (s, 1H), 7.33 (t, J = 7.4 Hz, 1H), 7.41 (t, J = 7.5 Hz, 
2H), 7.80 (s, 2H), 7.82 (s, 1H); 13C NMR (101 MHz, CDCl3) į 28.2, 28.7, 44.7, 50*, 
52.2, 68.2, 70.8, 80.5, 121.1, 125.9, 128.6, 129.2, 130.6, 148.0, 154.8; HRMS (ESI): 
m/z [M+Na]+ calcd for C19H26O3N4Na: 381.1897 found 381.1896. 
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trans-tert-Butyl 3-hydroxy-4-((4-methoxycarbonyl-1H-1,2,3-triazol-1-
yl)methyl)piperidine-1-carboxylate (52) 
1%RF
2+
1 1
1
  
2
2
Into a solution of 50 (0.568 g, 1.25 mmol) in dry THF (6 ml), TBAF (0.7 ml, 2.5 
mmol) was added slowly and stirred for overnight. Then water (5 ml) was added and 
extraction was done with ethyl acetate (10 ml x 3). The organic phase was washed 
with brine, dried over anhydrous MgSO4 and concentrated under reduced pressure. 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 7:3) to give 52 (0.358 g, 84%); Colorless solid; Rf = 0.14 (Hex/EtOAc, 7:3); 
mp 131-131.8 ºC; IR: 3390 (br), 3134 (w), 2929 (w), 2849 (w), 1727 (m), 1667 (s), 
1423 (s), 1365 (s), 1209 (s), 1155 (s), 1125 (m), 1042 (s), 954 (m), 872 (m), 775 (s) 
cm-1; 1H NMR (400 MHz, CDCl3) į 1.05 – 1.21 (m, 1H), 1.30 (s, 9H), 1.48 (d, J = 
13.2 Hz, 1H), 1.78 – 1.98 (m, 1H), 2.48 (br s, 2H), 3.24 (dt, J = 7.5 Hz, 1H), 3.81 (br 
s, 3H), 3.90 ( br s, 1H), 4.19 (s, 1H), 4.43 (dd, J = 11.1 Hz, 1H), 4.68 (dd, J = 8.1 Hz, 
1H), 8.20 (s, 1H); 13C NMR (101 MHz, CDCl3) į 27.7, 28.2, 43*, 44.1, 50*, 52.1, 
52.2, 67.6, 80.0, 128.7, 139.4, 154.4, 161.0; HRMS (ESI): m/z [M+Na]+ calcd for 
C15H24N4O5Na: 363.1639 found 363.1639.  
145
trans-tert-Butyl 3-(naphthalene-2-ylmethoxy)-4-((4-phenyl-1H-1,2,3-triazol-1-
yl)methyl)piperidine-1-carboxylate (53) 
1%RF
2
1 1
1
3K
  
A solution of 51 (0.101 g, 0.28 mmol) in DMF (2 ml) was added to a stirred 
suspension of NaH (22 mg, 0.92 mmol) in DMF (1 ml) and stirred for 30 min. 
Tetrabutylammonium iodide (10 mg, 0.03 mmol) and 2-bromomethylnaphthalene 
(0.124 g, 0.56 mmol) in DMF (2 ml) were added and the reaction mixture stirred for 
12 hr. The reaction mixture was diluted with EtOAc (10 ml) and poured into water (5 
ml). The solution was washed with 10% aq. HCl (3 ml), saturated aq. NaHCO3 (3 ml), 
and water (3 ml), dried over anhydrous MgSO4 and concentrated. Purification of the 
crude product with flash column chromatography using (hexane-EtOAc, 8:2) gave 53
( 0.128 g, 93%); Powdery solid; mp 130-130.7 ºC; Rf = 0.10 (Hex/EtOAc, 8:2); IR: 
3433 (br), 2973 (w), 2860 (w), 1682 (s), 1463 (m), 1421 (m), 1364 (m), 1241 (s), 
1154 (s), 1076 (s), 952 (m), 855 (m), 816 (m), 762 (s) cm-1; 1H NMR (400 MHz, 
CDCl3) į 1.11 – 1.32 (m, 2H), 1.44 (s, 9H), 2.04 (s, 1H), 2.50 – 2.60 (m, 2H), 3.20 
(td, J = 7.3 Hz, 1H), 4.01 (s, 1H), 4.37 (dd, J = 10.4 Hz, 1H), 4.52 – 4.71 (m, 2H), 
4.78 – 4.95 (m, 2H), 7.27 – 7.38 (m, 3H), 7.43 – 7.56 (m, 4H), 7.64 (s, 2H), 7.84 (m, 
4H); 13C NMR (101 MHz, CDCl3) į 27.8, 28.4, 43.1, 43.2, 51.5, 65.1, 71.3, 74.8, 
80.1, 120.3, 125.5, 126.1, 126.3, 126.4, 127.1, 127.8, 128.1, 128.6, 128.8, 130.5, 
133.2, 135.2, 147.6, 154.5; HRMS (ESI): m/z [M+Na]+ calcd for C30H34O3N4Na: 
521.2523 found 521.2527.  
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trans-tert-Butyl 4-((4-((naphthalen-1-ylmethoxy)carbonyl)-1H-1,2,3-triazol-1-
yl)methyl)-3-(naphthalen-2-ylmethoxy)piperidine-1-carboxylate (54) 
1%RF
2
1 1
1
2
2
  
A solution of  52 (0.174 g, 0.51 mmol) in DMF (2 ml) was added to a stirred 
suspension of NaH (40 mg, 1.68 mmol) in DMF (2 ml) and stirred for 30 min. 
Tetrabutylammonium iodide (18 mg, 0.05 mmol) and 2-bromomethylnaphthalene 
(0.225 g, 1.02 mmol) in DMF (2 ml) were added and the reaction mixture stirred for 
12 hr. The reaction mixture was diluted with EtOAc (10 ml) and poured into water 
(10 ml). The solution was washed with 10% aq. HCl (3 ml), saturated aq. NaHCO3 (3 
ml), and water (3 ml), dried over anhydrous MgSO4 and concentrated. Purification of 
the crude product with flash column chromatography using (hexane-EtOAc, 7:3) gave 
54 (0.145 g, 47%) and 55 (0.110 g, 47%); For 54; thick oil; Rf = 0.50 (Hex/EtOAc, 
7:3); IR: 3054 (w), 2973 (w), 2928 (w), 2860 (w), 1731 (w), 1683 (s), 1539 (w), 1422 
(m), 1364 (m), 1261 (m), 1155 (s), 1039 (m), 952 (w), 815 (s), 727 (s) cm-1; 1H NMR 
(400 MHz, CDCl3) į 1.13 – 1.31 (m, 1H), 1.43 (s, 9H), 1.52 (d, J = 12.9 Hz, 1H), 
2.02 – 2.09 (m, 1H), 2.51 – 2.60 (m, 2H), 3.16 (dt, J = 7.2 Hz, 1H), 4.01 (br s, 1H), 
4.30 – 4.36 (m, 1H), 4.64 (d, J = 11.0 Hz, 3H), 4.87 (d, J = 9.1 Hz, 1H), 5.51 (s, 2H), 
7.60 – 7.41 (m, 6H), 7.86 – 7.75 (m, 7H), 7.90 (s, 1H), 7.97 (s, 1H);  13C NMR (101 
MHz, CDCl3) į = 27.9, 28.4, 43.2, 46.4, 52.2, 67.1, 71.6, 75.2, 80.3, 125.9, 126.2, 
126.3, 126.4, 126.5, 127.0, 127.7, 127.8, 127.9, 128.0, 128.1, 128.4, 128.5, 128.6, 
132.9, 133.1, 133.2, 133.3, 135.1, 139.9, 154.5, 160.6; HRMS (ESI): m/z [M+Na]+
calcd for C36H38O5N4Na: 629.2734 found 629.2741. 
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trans-1-(tert-Butoxycarbonyl)-3-(naphthalen-2-ylmethoxy)piperidin-4-
yl)methyl)-1H-1,2,3-triazole-4-carboxylic acid (55) 
1%RF
2
1 1
1
+2
2
  
See description of synthesis of 54 for experimental details. For 55; White solid; mp 
120-120.5 ºC; Rf = 0.10 (Hex/EtOAc, 7:3); IR: 3378 (br), 3101 (w), 2931 (w), 2867 
(w), 1728 (s), 1681 (s), 1426 (s), 1364 (s), 1245 (m), 1199 (s), 1175 (s), 1127 (s), 
1055 (s), 1033 (m), 956 (m), 888 (m), 782 (m) cm-1; 1H NMR (400 MHz, CDCl3) į
1.11– 1.18 (m, 1H), 1.39 (s, 9H), 1.45 – 1.59 (m, 1H), 1.82 – 1.87 (m, 1H), 2.48 – 
2.54 (m, 2H), 3.24 – 3.29 (m, 1H), 3.99 – 4.11 (m, 1H), 4.28 (br s, 1H), 4.43 (dd, J = 
10.3 Hz, 1H), 4.62 (d, J = 12.0 Hz, 1H), 5.52 (s, 2H), 7.46 – 7.52 (m, 3H), 7.78 – 7.84 
(m, 3H), 7.89 (s, 1H), 8.11 (s, 1H); 13C NMR (101 MHz, CDCl3) į 28.1, 28.6, 43.7, 
44.5, 50.1, 52.4, 67.4, 67.9, 80.5, 126.4, 126.6, 126.7, 127.9, 128.2, 128.3, 128.7, 
128.9, 133.1, 133.4, 133.5, 139.9, 154.8, 160.8; HRMS (ESI): m/z [M+Na]+ calcd for 
C25H30O5N4Na: 489.2108 found 489.2106. 
trans-tert-Butyl 4-(azidomethyl)-3-hydroxypiperidine-1-carboxylate (56)
1%RF
2+
1
  
Into a solution of trans-48 (0.160 g, 0.43 mmol) in dry THF (4 ml), TBAF (0.12 ml, 
0.86 mmol) was added slowly and stirred for 24 hr. Then water (5 ml) was added and 
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extraction was done with ethyl acetate (10 ml x 3). The organic phase was washed 
with brine, dried over with anhydrous MgSO4 and concentrated under reduced 
pressure. Purification of the crude product with flash column chromatography using 
(hexane-EtOAc, 7:3) gave 56 (90 mg, 81%); Clear oil; Rf = 0.45; IR: 3400 (br), 2976 
(w), 2927 (w), 2095 (s), 1662 (s), 1426 (s), 1366 (s), 1244 (m), 1162 (s), 1131 (s), 
1056 (m), 956 (m), 881 (w), 832 (s), 768 (w) cm-1; 1H NMR (400 MHz, CDCl3) į
1.22 – 1.39 (m, 2H), 1.44 (s, 9H), 1.57– 1.62 (m, 1H), 1.67 – 1.74 (m, 1H), 2.51 (s, 
1H), 2.67 (br s, 1H), 3.44 (dt, J = 7.0 Hz, 2H), 3.54 (s, 1H), 4.10 (s, 1H), 4.23 (s, 1H); 
13C NMR (101, MHz, CDCl3) į 27.9, 28.5, 43.5, 44*, 50.0, 53.9, 68*, 80.2, 154.7; 
HRMS (ESI): m/z [M+Na]+ calcd for C11H20N4O3Na: 279.1428 found 279.1431.  
trans-tert-Butyl 4-(azidomethyl)-3-(naphthalene-2-ylmethoxy)piperidine-1-
carboxylate (57)
A solution of  56 (84 mg, 0.33 mmol) in DMF (2 ml) was added to a stirred 
suspension of NaH (26 mg, 1.09 mmol) in DMF (1 ml) and stirred for 30 min. 
Tetrabutylammonium iodide (12 mg, 0.03 mmol) and 2-bromomethylnaphthalene 
(0.145 g, 0.66 mmol) in DMF (2 ml) were added and the reaction mixture stirred for 
overnight. The reaction mixture was diluted with EtOAc (10 ml) and poured into 
water (10 ml). The solution was washed with 10% aq. HCl (3 ml), saturated aq. 
NaHCO3 (3 ml), and water (3 ml), dried over anhydrous MgSO4 and concentrated. 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 8:2) gave 57 (0.129 g, 99%); Thick paste; Rf = 0.90; IR: 2922 (w), 2856 (w), 
2095 (s), 1689 (s), 1421 (s), 1365 (s), 1272 (w), 1244 (m), 1163 (s), 1141 (s), 1080 
(m), 953 (w), 888 (w), 855 (w),  817 (m), 751 (m) cm-1; 1H NMR (400 MHz, CDCl3) 
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į 1.21 – 1.34 (m, 2H), 1.47 (s, 9H), 1.68 – 1.77 (m, 1H), 2.48 – 2.63 (m, 1H), 2.68 (br 
s, 1H), 3.25 (s, 1H), 3.41 (dd, J = 9.0 Hz, 1H), 3.57 (dd, J = 7.0 Hz, 1H), 4.07 – 4.16 
(m, 1H), 4.66 (d, J = 11.0 Hz, 1H), 4.78 (br s, 1H), 4.85 (s, 1H), 7.44 – 7.54 (m, 3H), 
7.79 (s, 1H), 7.86 (t, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) į 27.9, 28.4, 42.5, 
44*, 53.1, 71.7, 72.2, 74.8, 79.9, 125.9, 126.2, 126.6, 126.8, 127.7, 127.9, 128.3, 
133.0, 133.2, 135.4, 154.5; HRMS (ESI): m/z [M+Na]+ calcd for C22H28N4O3Na: 
419.2054 found 419.2057. 
trans-tert-Butyl 4-((4-(methoxycarbonyl)-1H-1,2,3-triazol-1-yl)methyl)-3-
(naphthalen-2-ylmethoxy)piperidine-1-carboxylate (58)
1%RF
2
1 1
1
2
2
  
A mixture of azide 57 (0.129 g, 0.33 mmol), methyl propiolate (42 mg, 0.50 mmol), 
CuSO4 .5H2O (3 mg, 0.01 mmol) and Na-ascorbate (7 mg, 0.03 mmol) in 
dioxane/water (4 ml, 3:1) was stirred for 18 hr at 65 ºC. The extraction was done with 
ethyl acetate (5 ml x 3). The combined organics were washed with brine, dried over 
anhydrous MgSO4 and concentrated. Purification of the crude product with flash 
column chromatography using (hexanes-EtOAc, 7:3) gave 58 (0.138 g, 88%); Yellow 
oil; Rf = 0.17; 1H NMR (400 MHz, CDCl3) į 1.24 (t, J = 7.0 Hz, 2H), 1.42 (s, 9H), 
2.05 – 2.10 (m, 1H), 2.45 – 2.70 (m, 2H), 3.16 (dt, J = 7.2 Hz, 1H), 3.87 (s, 3H), 3.94 
– 4.20 (m, 2H), 4.35 (dd, J = 10.0 Hz, 1H), 4.65 (d, J = 10.4 Hz, 2H),  4.86 (s, 1H), 
7.39 – 7.57 (m, 3H), 7.77 – 7.82 (m, 4H), 7.95 (s, 1H); 13C NMR (101 MHz, CDCl3) 
į 21.3, 28.1, 28.6, 43.4, 46*, 52.4, 60.7, 71.7, 75.4, 80.4, 126.2, 126.5, 126.6, 127.2, 
150
128.1, 128.2, 128.5, 128.8, 133.4, 133.5, 135.3, 140.1, 154.6, 161.3; HRMS (ESI): 
m/z [M+H]+ cald for C26H33O5N4: 461.2450 found 461.2448. 
trans-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-((5-phenyl-1H-1,2,3-triazol-1-
yl)methyl)piperidine-1-carboxylate (59)
1%RF
27%'06
1 1
1
3K
  
A mixture of trans-48 (0.233 g, 0.63 mmol), phenyl acetylene (96 mg, 0.95 mmol) 
and Cp*RuCl(PPh3)2 (5 mg) in C6H6 (6 ml) was refluxed for 4 hr under N2. Then the 
solvent was removed under reduced pressure. Purification of the crude product with 
flash column chromatography using (hexane-EtOAc Purification with flash column 
(Hex/EtOAc, 8:2) gave 59 (0.263 g, 89%); Reddish brown oil; Rf = 0.20; IR: 2953 
(w), 2928 (w), 2856 (w), 1690 (s), 1461 (w), 1417 (m), 1364 (m), 1245 (s), 1154 (s), 
1111 (m), 1083 (s), 959 (m), 830 (s), 768 (s), 698 (m) cm-1; 1H NMR (400 MHz, 
CDCl3) į 0.07 (d, 6H), 0.84 (s, 9H), 1.07 (m, 1H), 1.23 (s, 1H), 1.40 (s, 9H), 1.80-
2.01 (m, 1H), 2.35-2.52 (m, 2H), 3.25-3.33 (m, 1H), 3.93 (br s, 1H), 4.08 (dd, J = 
12.0 Hz, 2H), 4.77 (d, J = 12.7 Hz, 1H), 7.32 – 7.42 (m, 2H), 7.51 – 7.42 (m, 3H),
7.68 (s, 1H); 13C NMR (101 MHz, CDCl3) į -4.0, 17.9, 25.8, 27.6, 28.4, 42*, 44.9, 
50.2, 51*, 70.1, 79.9, 127.1, 128.8, 129.3, 129.6, 133.2, 138.2, 154.4; HRMS (ESI): 
m/z [M+H]+ cald for C25H41O3N4Si: 473.2947 found 473.2927.  

151
trans-tert-Butyl 3-hydroxy-4-((5-phenyl-1H-1,2,3-triazol-1-yl)methyl)piperidine-
1-carboxylate (60) 
1%RF
2+
1 1
1
3K
  
Into a solution of 59 (0.250 g, 0.53 mmol) in dry THF (5 ml), TBAF (0.31 ml, 1.06 
mmol) was added slowly and stirred for 24 hr. Then water (5 ml) was added and 
extraction was done with ethyl acetate (10 ml x 3). The organic phase was washed 
with brine, dried over with anhydrous MgSO4 and concentrated under reduced 
pressure. Purification of the crude product with flash column chromatography using 
(hexane-EtOAc, 7:3) to give 60 (0.170 g, 89%); Red brown oil; Rf = 0.10; IR: 3450 
(w), 2974 (w), 2917 (w), 1681 (s), 1419 (s), 1365 (m), 1237 (m), 1153 (w), 1056 (m), 
954 (w), 768 (m), 729 (m), 697 (m) cm-1; 1H NMR (400 MHz, CDCl3) į 1.01 (s, 1H), 
1.22 (s, 1H), 1.37 (s, 9H), 1.87 – 2.07 (m, 1H), 2.49 (br s, 2H), 3.30 – 3.35 (m, 1H), 
3.91 (br s, 2H), 4.22 – 4.30 (m, 2H), 4.77 (br s, 1H), 7.44 (m, 5H), 7.65 (s, 1H); 13C 
NMR (101 MHz, CDCl3) į 27.8, 28.4, 44.3, 50.1, 51*, 68.6, 79.9, 126.9, 129.0, 
129.2, 129.6, 132.9, 138.7, 154.5; HRMS (ESI): m/z [M+H]+ cald for C19H27O3N4: 
359.2083 found 359.2068.  
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trans-tert-Butyl 3-(naphthalene-2-ylmethoxy)-4-((5-phenyl-1H-1,2,3-triazol-1-
yl)methyl)piperidine-1-carboxylate (61) 
1%RF
2
1 1
1
3K
  
A solution of 60 (0.160 g, 0.45 mmol) in DMF (2 ml) was added to a stirred 
suspension of NaH (36 mg, 1.49 mmol) in DMF (1 ml) and stirred for 30 min. 
Tetrabutylammonium iodide (17 mg, 0.04 mmol) and 2-bromomethylnaphthalene 
(0.199 g, 0.90 mmol) in DMF (2 ml) were added and the reaction mixture was stirred 
for overnight. The reaction mixture was diluted with EtOAc (5 ml) and poured into 
water (5 ml). The solution was washed with 10% aq. HCl (3 ml), saturated aq. 
NaHCO3 (3 ml), and water (3 ml), dried over anhydrous MgSO4 and concentrated. . 
Purification of the crude product with flash column chromatography using (hexane-
EtOAc, 7:3) gave 61 (0.200 g, 89%); Thick yellow oil; Rf = 0.35; IR: 2973 (w), 2919 
(w), 2860 (w), 1687 (s), 1422 (m), 1365 (m), 1245 (m), 1154 (s), 1086 (m), 769 (w), 
698 (w) cm-1; 1H NMR (400 MHz, CDCl3) į 1.02 – 1.10 (s, 1H), 1.25 (s, 1H), 1.42 (s, 
9H), 1.53 (br s, 1H), 2.09 –  2.14 (m, 1H), 2.54 – 2.67 (m, 2H), 3.23 (dt, J = 7.2 Hz, 
1H), 3.94 (br s, 1H), 4.15 (br s, 1H), 4.59 (br s, 1H), 4.78 – 4.85 (m, 2H), 7.30 – 7.41 
(m, 5H), 7.54 – 7.47 (m, 2H), 7.68 (s, 1H), 7.71 (s, 1H), 7.81 (m, 3H); 13C NMR (101 
MHz, CDCl3) į 27.8, 28.4, 43.0, 49.7, 71.4, 75.5, 80.1, 125.9, 126.1, 126.3, 126.7, 
127.0, 127.8, 127.9, 128.3, 128.9, 129.2, 129.5, 133.1, 133.3, 135.5, 138.4, 154.6; 
HRMS (ESI): m/z [M+H]+ cald for C30H35O3N4: 499.2709 found 499.2704. 
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trans-3-(Naphthalen-2-ylmethoxy)-4-((4-phenyl-1H-1,2,3-triazol-1-
yl)methyl)piperidine (62) 
1+
2
1 1
1
3K
  
[&)&22+
The solution of 53 (0.144 g, 0.29 mmol) in 2 ml of CH2Cl2/TFA (1:1) was stirred for 
30 min. The solvent was removed under reduced pressure. The toluene (5 ml x 2), 
acetonitril (5 ml x 2) and CH2Cl2 (5 ml x 2) were added and removed under reduced 
pressure. Purification using semi-preparative HPLC gave 62 (49 mg, 34%) after 
lyophilization. 1H NMR (400 MHz, MeOD) į 1.28 – 1.35 (m, 1H), 1.40 – 1.52 (m, 
1H), 1.80 – 2.05 (m, 1H), 2.30 – 2.37 (m, 1H), 2.79 – 3.02 (m, 2H), 3.58 – 3.65 (m, 
2H), 4.54 (dd, J = 14.1, 6.9 Hz, 1H), 4.69 – 4.81 (m, 3H), 7.29 – 7.40 (m, 3H), 7.43 – 
7.57 (m, 3H), 7.65 (d, J = 7.0 Hz, 2H), 7.73 – 7.90 (m, 5H), 8.09 (s, 1H); 13C NMR 
(101 MHz, CDCl3) į 24.5, 40.6, 42.7, 45.8, 50.9, 71.6, 72.7, 121.9, 125.5, 126.1, 
126.2, 126.3, 127.1, 127.6, 127.9, 128.2, 128.3, 128.8, 130.3, 133.5, 133.6, 135.3, 
147.7; HRMS (ESI): m/z [M+H]+ cald for C25H27ON4: 399.2179 found 399.2181. 
trans-Methyl-3-(naphthalen-2-ylmethoxy)piperidin-4-yl)methyl)-1H-1,2,3-
triazole-4-carboxylate (63) 
1+
2
1 1
1
2
2
  
[&)&22+
154
The solution of 58 (0.126 g, 0.26 mmol) in 2 ml of CH2Cl2/TFA (1:1) was stirred for 
30 min. The solvent was removed under reduced pressure. The toluene (5 ml x 2), 
acetonitril (5 ml x 2) and CH2Cl2 (5 ml x 2) were added and removed under reduced 
pressure. Purification using semi-preparative HPLC gave 63 (72 mg, 58%) after 
lyophilization. 1H NMR (400 MHz, MeOD) į 1.45 – 1.52 (m, 1H), 1.96 (dd, J = 9.2 
Hz, 1H), 2.40 – 2.52 (m, 1H), 2.87 – 3.07 (m, 2H), 3.52 – 3.86 (m, 2H), 3.80 (s, 3H), 
4.50 – 4.58 (m, 1H), 4.72 (dd, J = 9.2 Hz, 2H), 4.78 – 4.82 (m, 2H), 7.42 – 7.52 (m, 
3H), 7.77 (s, 1H), 7.84 (m, 3H), 8.44 (s, 1H); 13C NMR (101 MHz, MeOD) į  24.8, 
41.1, 43.4, 46.3, 52.1, 52.5, 72.9, 73.4, 127.1, 127.3, 127.4, 128.1, 128.8, 128.9, 
129.4, 130.4, 134.6, 134.7, 136.1, 140.5, 162.2; HRMS (ESI): m/z [M+H]+ cald for 
for C21H25O3N4: 381.1921 found 381.1920.  
trans-3-(naphthalen-2-ylmethoxy)-4-((5-phenyl-1H-1,2,3-triazol-1-
yl)methyl)piperidine (62) 
1+
2
1 1
1
3K
  
[&)&22+
The solution of 61 (0.187 g, 0.38 mmol) in 2 ml of CH2Cl2/TFA (1:1) was stirred for 
30 min. The solvent was removed under reduced pressure. The toluene (5 ml x 2), 
acetonitril (5 ml x 2) and CH2Cl2 (5 ml x 2) were added and removed under reduced 
pressure. Purification using preparative HPLC gave 64 (80 mg, 42%) after 
lyophilization. 1H NMR (400 MHz, MeOD) į 1.31 – 1.48 (m, 1H), 1.77 – 1.96 (m, 
1H), 2.14 – 2.22 (m, 1H), 2.82 – 2.92 (m, 2H), 3.15 – 3.21 (m, 1H), 3.52 (dd, J = 9.0, 
4.5 Hz, 2H), 4.34 (dd, J = 14.3, 8.4 Hz, 1H), 4.60 (d, J = 11.7 Hz, 1H), 4.71 – 4.84 
(m, 2H), 7.30 – 7.40 (m, 6H), 7.44 – 7.61 (m, 2H), 7.72 (s, 2H), 7.75 – 7.93 (m, 3H);  
13C NMR (101 MHz, CDCl3) į 23.6, 39.7, 41.9, 44.8, 49*, 71.6, 71.7, 125.8, 126.1, 
155
126.2, 126.9, 127.5, 127.7, 128.2, 128.8, 129.1, 129.6, 132.6, 133.4, 134.9, 138.9; 
HRMS (ESI): m/z [M+H]+ cald for C25H27ON4: 399.2179 found 399.2182.  
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